Professor Michael J Cork

BSc MB PhD FRCP

Clinical Medicine, School of Medicine and Population Health

Professor of Dermatology

M.J.Cork@sheffield.ac.uk

+44 114 215 9576 (Clerical Assistant - Les Hunter)

The Medical School

Full contact details

Professor Michael J Cork
Clinical Medicine, School of Medicine and Population Health
The Medical School
Beech Hill Road
Sheffield
S10 2RX

Profile

For enquiries please contact - ClinMed-Operational@sheffield.ac.uk

I joined the University of Sheffield in 1991 as a lecturer in dermatology whilst continuing as a practising dermatologist for the NHS in Sheffield. I had previously been a Registrar in Dermatology at the Royal Hallamshire Hospital, Sheffield, and before that a Registrar in Respiratory General Medicine at Leeds General Infirmary.

I have been closely involved with research in many areas of dermatology; including Atopic Eczema(dermatitis), Psoriasis, Vitiligo and the Genetics of Skin Disease. My major current research work is aimed at identifying gene–environment interactions in the development of atopic dermatitis leading to skin barrier breakdown and the understanding of how topical agents interact with the skin barrier; using this information to enhance the treatment of atopic dermatitis.

I am currently Head of Sheffield Dermatology Research in the School of Medicine & Population Health at the University of Sheffield and am Honorary Consultant Dermatologist to both Sheffield Children´s Hospital NHS Foundation Trust and to Sheffield Teaching Hospitals NHS Foundation Trust; my time is evenly split between the University and the NHS.

Research interests

My research interests are inflammatory skin disorders including: atopic dermatitis (atopic eczema), psoriasis, alopecia areata and vitiligo. The group which includes both clinical and non-clinical staff has identified genetic variants associated with all of these diseases.

Internationally, Sheffield Dermatology Research is one of the leading groups translating basic dermatological science into new treatments for the clinic. Examples include `Skin Protease Inhibitors´ and `Vitamin A Metabolic Pathway Inhibitors´. In 2001, with help from The Wellcome Trust, the group formed a `spin-out´ company called `Molecular SkinCare´, with the aim of developing these treatments.

Another major focus of the group is the effect of topical pharmaceuticals, cosmetics and oils on the structure and function of the skin barrier. Research in this area comprises investigation of the skin barrier defect associated with skin disorders such as atopic dermatitis, how skin barrier defects develop and how to treat or repair the skin barrier defect. This includes the determination of the effect of topical agents/products on the skin of volunteers visiting our clinical diagnostic `skin laboratory´, where we can measure specific properties of the skin barrier, non-invasively, using an array of specialised equipment. These results are then correlated with variants in the genes that determine the structure and function of the skin barrier.

Research conducted by Sheffield Dermatology Research is at the interface between the clinic, academia and industry. Work has been funded by charities, including: The Wellcome Trust, British Skin Foundation and Psoriasis Association; also by the Kuwait Ministry of Health; and by pharmaceutical/cosmetics companies; including Astellas, Johnson & Johnson and Stiefel-GSK.

Publications

Show: Featured publications All publications

Featured publications

Journal articles

Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Soong W, Gonzalez ME, Schneider LC, Sidbury R , Lockshin B et al (2022) Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 400(10356), 908-919.
Chalmers JR, Haines RH, Bradshaw LE, Montgomery AA, Thomas KS, Brown SJ, Ridd MJ, Lawton S, Simpson EL, Cork MJ , Sach TH et al (2020) Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. The Lancet, 395(10228), 962-972.
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP , Kingo K et al (2016) Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. New England Journal of Medicine, 375, 2335-2348. View this article in WRRO
Chittock J, Cooke A, Lavender T, Brown K, Wigley A, Victor S, Cork MJ & Danby SG (2016) Development of stratum corneum chymotrypsin-like protease activity and natural moisturizing factors from birth to 4 weeks of age compared with adults. British Journal of Dermatology, 175(4), 713-720. View this article in WRRO
Danby SG, Brown K, Higgs-Bayliss T, Chittock J, Albenali L & Cork M (2016) The Effect of an Emollient Containing Urea, Ceramide NP, and Lactate on Skin Barrier Structure and Function in Older People with Dry Skin. Skin Pharmacology and Physiology, 29(3), 135-147. View this article in WRRO
Cooke A, Cork M, Victor S, Campbell M, Danby S, Chittock J & Lavender T (2016) Olive Oil, Sunflower Oil or no Oil for Baby Dry Skin or Massage: A Pilot, Assessor-blinded, Randomized Controlled Trial (the Oil in Baby SkincaRE [OBSeRvE] Study). Acta Dermato Venereologica, 96(3), 323-330.
Chittock J, Brown K, Cork M & Danby S (2015) Comparing the Effect of a Twice-weekly Tacrolimus and Betamethasone Valerate Dose on the Subclinical Epidermal Barrier Defect in Atopic Dermatitis. Acta Dermato Venereologica, 95(6), 653-658.
Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WHI, Brown SJ, Chen Z, Chen Y & Williams HC (2014) Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology, 134(4), 818-823.
Danby SG, Chittock J, Brown K, Albenali LH & Cork MJ (2014) The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis.. Br J Dermatol, 170(4), 914-921.
Mason AR, Mason J, Cork MJ, Dooley G & Hancock H (2013) Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev..
Lavender T, Bedwell C, Roberts SA, Carter L-A, Hart A, Turner MA & Cork MJ (2013) Randomized, Controlled Trial Evaluating a Baby Wash Product on Skin Barrier Function in Healthy, Term Neonates. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing. View this article in WRRO
Danby SG, AlEnezi T, Sultan A, Lavender T, Chittock J, Brown K & Cork MJ (2013) Effect of olive and sunflower seed oil on the adult skin barrier: implications for neonatal skin care.. Pediatr Dermatol, 30(1), 42-50.
Danby SG, Al-Enezi T, Sultan A, Chittock J, Kennedy K & Cork MJ (2011) The effect of aqueous cream BP on the skin barrier in volunteers with a previous history of atopic dermatitis.. Br J Dermatol, 165(2), 329-334.
Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M, Guy RH, Macgowan AL, Tazi-Ahnini R & Ward SJ (2009) Epidermal barrier dysfunction in atopic dermatitis.. J Invest Dermatol, 129(8), 1892-1908.
Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Hultsch T, Davis JD, Zhang Y, Zhu X, Chen Z, Li M , Ardeleanu M et al () Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis : results from a phase IIa open‐label trial and subsequent phase III open‐label extension. British Journal of Dermatology. View this article in WRRO

Chapters

Danby S, Bedwell C & Cork MJ (2014) Neonatal Skin Care and Toxicology In Eichenfield LF, Frieden IJ, Zaenglein A & Mathes E (Ed.), Neonatal and Infant Dermatology (pp. 46-56). Saunders
Cork MJ & Danby S (2011) The Skin Barrier in Atopic Dermatitis. In Irvine A, Hoeger P & Yan A (Ed.), Textbook of Pediatric Dermatology, UK: Blackwell Publishing Ltd..

Reports

Danby SG, Ewence A, Rumsby P, Cork MJ, Williams HC, Rockett L & Davey HMSAUIII-PP (2011) A systematic review of skin irritation and tap water

All publications

Journal articles

Alshiyab D, Ba-Shammakh SA, Al-Fakih A, Tashman O, Sarakbi D, Al-Qarqaz F, Muhaidat J, Atwan A & Cork MJ (2024) Efficacy and safety of 308-nm Excimer lamp combined with Tacrolimus 0.1% ointment vs Tacrolimus 0.1% ointment as monotherapy in treating children with limited vitiligo: a randomized controlled trial.. J Dermatolog Treat, 35(1), 2296851.
Paller A, Cork M, Hong C-H, Soong W, Schneider S, Lo H, Pedersen LRM, Vacko E & Wollenberg A (2024) 549 - Laboratory parameters in adolescent patients aged 12–17 with moderate-to-severe atopic dermatitis treated with tralokinumab up to week 52: results from the phase 3 ECZTRA 6 trial. British Journal of Dermatology, 190(Supplement_2), ii47-ii48.
Bronova I, Berdyshev E, Goleva E, Danby S, Bronoff AS, Richers B, Garcia S, Gama MR, Taylor P, Zahn J , Agueusop I et al (2024) Dupilumab Improves Skin Lipid Barrier in Pediatric Patients With Moderate-to-Severe Atopic Dermatitis. Journal of Allergy and Clinical Immunology, 153(2), AB5-AB5.
Khemis A, Simpson E, Wollenberg A, Bewley A, Cork MJ, Hong CH, Soong W, Almgren P, Gjerum L, Carlsson A , Paller AS et al (2023) Tolérance et efficacité à long terme du tralokinumab chez des adolescents atteints de dermatite atopique modérée à sévère : analyse intermédiaire d’ECZTEND. Annales de Dermatologie et de Vénéréologie - FMC, 3(8), A363-A364.
Chittock J, Kay L, Brown K, Cooke A, Lavender T, Cork MJ & Danby SG (2023) ASSOCIATION BETWEEN SKIN BARRIER DEVELOPMENT AND EARLY-ONSET ATOPIC DERMATITIS: A LONGITUDINAL BIRTH COHORT STUDY. Journal of Allergy and Clinical Immunology.
Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Chen Z, Thomas RB, Kosloski MP, Dubost-Brama A, Prescilla R, Bansal A & Levit NA (2023) Dupilumab safety and efficacy in a phase III open-label extension trial in children 6–11 years of age with severe atopic dermatitis. Dermatology and Therapy, 13, 2697-2719. View this article in WRRO
Flohr C, Rosala-Hallas A, Jones AP, Beattie P, Baron S, Browne F, Brown SJ, Gach JE, Greenblatt D, Hearn R , Hilger E et al (2023) Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial. British Journal of Dermatology, ljad281.
Zuberbier T, Abdul Latiff A, Aggelidis X, Augustin M, Balan R, Bangert C, Beck L, Bieber T, Bernstein JA, Bertolin Colilla M , Berardi A et al (2023) A concept for integrated care pathways for atopic dermatitis—A GA2LEN ADCARE initiative. Clinical and Translational Allergy, 13(9). View this article in WRRO
Sach TH, Lartey ST, Davies C, Chalmers JR, Haines RH, Bradshaw LE, Montgomery AA, Thomas KS, Brown SJ, Ridd MJ , Lawton S et al (2023) Emollients for preventing atopic eczema: cost‐effectiveness analysis of the BEEP trial. Clinical & Experimental Allergy. View this article in WRRO
Siegfried EC, Simpson EL, Cork MJ, Arkwright PD, Wine Lee L, Chen Z, Prescilla R, Bansal A, Levit NA & Rodríguez Marco A (2023) Dupilumab Treatment Leads to Rapid and Consistent Improvement of Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 Years. Dermatology and Therapy, 13(9), 1987-2000. View this article in WRRO
Weidinger S, Bieber T, Cork MJ, Reich A, Wilson R, Quaratino S, Stebegg M, Brennan N, Gilbert S, O’Malley JT & Porter-Brown B (2023) Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial. British Journal of Dermatology, 189(5), 531-539.
Duan MQ, Byers RA, Danby SG, Sahib S, Cha A, Zang C, Werth J, Adiri R, Taylor RN, Cork MJ & Matcher SJ (2023) Potential application of PS-OCT in the safety assessment of non-steroidal topical creams for atopic dermatitis treatment. Biomedical Optics Express, 14(8), 4126-4126.
Paller AS, Flohr C, Cork M, Bewley A, Blauvelt A, Hong HC-H, Imafuku S, Schuttelaar MLA, Simpson EL, Soong W , Arlert P et al (2023) Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis. JAMA Dermatology, 159(6), 596-596.
Siegfried EC, Cork MJ, Katoh N, Zhang H, Chuang C-C, Thomas RB, Rossi AB, Cyr SL & Zhang A (2023) Dupilumab provides clinically meaningful responses in children aged 6–11 years with severe atopic dermatitis: post hoc analysis results from a phase III trial. American Journal of Clinical Dermatology, 24(5), 787-798. View this article in WRRO
Winder N, Ashraf Z, Gohar S, Baalbaki N, Cork M, Danby S & Muthana M (2023) Are mild cleansers appropriate for hand hygiene in the COVID era? An in vitro investigation of the antiviral efficacy of different hand hygiene products. Frontiers in Virology, 3. View this article in WRRO
Simpson EL, Silverberg JI, Thyssen JP, Viguier M, Thaçi D, de Bruin-Weller M, Weidinger S, Chan G, DiBonaventura M, Biswas P , Feeney C et al (2023) Efficacy and safety of abrocitinib in patients with severe and/or difficult-to-treat atopic dermatitis: a post hoc analysis of the randomized phase 3 JADE COMPARE trial. American Journal of Clinical Dermatology, 24, 609-621. View this article in WRRO
Flohr C, Irvine AD, Cork MJ, Simpson EL, Wollenberg A, Deleuran M, Praestgaard A, Thomas RB & Rossi AB (2023) Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6–11 years with severe atopic dermatitis. British Journal of Dermatology, 189(2), 238-240.
Flohr C, Cork MJ, Ardern-Jones MR, Eichenfield LF, Barbarot S, Feeney C, Rojo R, Lazariciu I & Nesnas J (2023) Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial. Journal of Dermatological Treatment, 34(1).
Bieber T, Thyssen JP, Irvine AD, Tsunemi Y, Chen Y-F, Sun L, Schloebe A, Riedl E & Cork MJ (2023) Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis. Clinical and Experimental Dermatology, 48(8), 881-888.
Siegfried EC, Cork MJ, Boguniewicz M, Deleuran M, Simpson EL, Rossi A, Chen Z, Clearfield D, Shah P & Marco AR (2023) Dupilumab treatment reduces total IgE levels in patients 6 months and older with moderate-to-severe atopic dermatitis. Revue Française d'Allergologie, 63(3), 103434-103434.
Cork MJ, Wollenberg A, Siegfried EC, Rossi AB, Chen Z, Levit NA & Marco AR (2023) Dupilumab treatment in children aged 6–11 years with severe atopic dermatitis is associated with reductions in serum immunoglobulin E and thymus and activation-regulated chemokine levels. Revue Française d'Allergologie, 63(3), 103436-103436.
Zuberbier T, Beck LA, Bedbrook A, de Bruin‐Weller M, Bousquet J, Cork M, Douladiris N, Katoh N, Mortz CG, Werfel T , Wojciech F et al (2023) Developing integrated care pathways for atopic dermatitis—challenges and unmet needs. Clinical and Translational Allergy, 13(3).
van den Bogaard EH, Elias PM, Goleva E, Berdyshev E, Smits JPH, Danby SG, Cork M & Leung DYM (2023) Targeting skin barrier function in atopic dermatitis. The Journal of Allergy and Clinical Immunology: In Practice.
Schachner L, Alexis A, Andriessen A, Baldwin H, Cork M, Kirsner R & Woolery-Lloyd H (2023) Supplement Individual Article: The Importance of a Healthy Skin Barrier From the Cradle to the Grave Using Ceramide-Containing Cleansers and Moisturizers: A Review and Consensus. Journal of drugs in dermatology : JDD, 22(2), s3-SF344607s.
Siegfried E, Cork M, Boguniewicz M, Deleuran M, Simpson E, Chen Z, Clearfield D, Shah P & Rodriguez-Marco A (2023) Dupilumab Treatment Reduces Total IgE Levels in Patients 6 Months and Older with Moderate-to-Severe Atopic Dermatitis. Journal of Allergy and Clinical Immunology, 151(2), AB149-AB149.
Paller AS, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Gonzalez ME, Lockshin B, Chen Z, Bansal A, Levit NA & Prescilla R (2023) Laboratory safety from a randomized 16-week phase III study of dupilumab in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis. Pediatric Drugs, 25, 67-77.
Chittock J, Cork MJ & Danby SG (2022) REAL-TIME INFRARED Spectroscopic measurement of Natural Moisturising Factor. Journal of Investigative Dermatology.
Thyssen JP, Silverberg J, Cork MJ, Taieb A, Malhotra BK, Johnson SL, Fostvedt L, Feeney C & Biswas P (2022) Efficacité et tolérance de l’abrocitinib selon le poids corporel : analyse poolée de 3 essais cliniques randomisés. Annales de Dermatologie et de Vénéréologie - FMC, 2(8), A342-A343.
Simpson E, Silverberg J, Zdybski J, Cork MJ, Paul C, Feeney C, Clibborn C, Dibonaventura M, Biswas P & Guler E (2022) Résultats d’abrocitinib chez les patients atteints de dermatite atopique et d’asthme : analyse de l’essai JADE REGIMEN. Annales de Dermatologie et de Vénéréologie - FMC, 2(8), A335-A336.
Bradshaw LE, Wyatt LA, Brown SJ, Haines RH, Montgomery AA, Perkin MR, Lawton S, Sach TH, Chalmers JR, Ridd MJ , Flohr C et al (2022) Emollients for prevention of atopic dermatitis; 5‐year findings from the BEEP randomised trial. Allergy.
Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Soong W, Gonzalez ME, Schneider LC, Sidbury R , Lockshin B et al (2022) Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 400(10356), 908-919.
Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J, Browning J, Soong W, Sun X, Chen Z , Kosloski MP et al (2022) Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis : results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE). American Journal of Clinical Dermatology, 23(3), 365-383.
Beck LA, Cork MJ, Amagai M, De Benedetto A, Kabashima K, Hamilton JD & Rossi AB (2022) Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis. JID Innovations.
Cork MJ, Guttman-Yassky E, Simpson EL, Soong W, Wang Z, Chuang CC, O’malley JT & Bansal A (2022) Efficacy and safety of dupilumab in children aged 6–11 years with inadequately controlled severe atopic dermatitis: Results from an open-label extension trial up to 1 year. Revue Française d'Allergologie et d'Immunologie Clinique, 62(3), 321.
Katibi OS, Cork MJ, Flohr C & Danby SG (2022) Moisturizer therapy in prevention of atopic dermatitis and food allergy: to use or disuse?. Annals of Allergy, Asthma & Immunology.
Danby SG, Andrew PV, Taylor RN, Kay LJ, Chittock J, Pinnock A, Ulhaq I, Fasth A, Carlander K, Holm T & Cork MJ (2022) Different types of emollient cream exhibit diverse physiological effects on the skin barrier in adults with atopic dermatitis. Clinical and Experimental Dermatology. View this article in WRRO
Danby SG, Andrew PV, Kay LJ, Pinnock A, Chittock J, Brown K, Williams SF & Cork MJ (2021) Enhancement of stratum corneum lipid structure improves skin barrier function and protects against irritation in adults with dry, eczema‐prone, skin. British Journal of Dermatology. View this article in WRRO
Bewley A, Pontoppidan Thyssen J, Sin Chiu W, Rojo R, Biswas P, Feeney C, Dibonaventura M, Misery L, Staender S & Cork MJ (2021) Impact de l’abrocitinib sur les démangeaisons, le sommeil, la douleur cutanée et le stress psychologique chez les patients présentant une dermatite atopique modérée à sévère : analyse poolée des essais JADE en monothérapie. Annales de Dermatologie et de Vénéréologie - FMC, 1(8), A345-A346.
Cork MJ, Eichenfield L, Flohr C, Bangert C, Barbarot S, Chan GL, Rojo R, Zhang F, Feeney C & Valdez H (2021) Impact de l’abrocitinib sur la réponse vaccinale chez les adolescents présentant une dermatite atopique modérée à sévère recevant les vaccins courants contre la diphtérie, la coqueluche et le tétanos dans l’étude de phase III JADE TEEN. Annales de Dermatologie et de Vénéréologie - FMC, 1(8), A354-A355.
Flohr C, Cork MJ, Ardern Jones MR, Barbarot S, Feeney C, Rojo R, Biswas P & Nesnas J (2021) Induction par l’abrocitinib, arrêt de la thérapie et récupération de l’efficacité par traitement de secours chez les adolescents présentant une dermatite atopique modérée à sévère : analyse post-hoc de l’étude de phase 3 JADE-REGIMEN (NCT036227767). Annales de Dermatologie et de Vénéréologie - FMC, 1(8), A348-A348.
Zuberbier T, Dörr T, Aberer W, Alvaro M, Angier E, Arasi S, Arshad H, Ballmer‐Weber B, Bartra J, Beck L , Bégin P et al (2021) Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper. Allergy.
Cork MJ, McMichael A, Teng J, Valdez H, Rojo R, Chan G, Zhang F, Myers DE & DiBonaventura M (2021) Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate‐to‐severe atopic dermatitis : an analysis of patient‐reported outcomes. Journal of the European Academy of Dermatology and Venereology.
Paller A, Beck L, Blauvelt A, Cork M, Wollenberg A, Chen Z, Bates L, Cyr S & Zhang A (2021) D040 INFECTIONS IN DUPILUMAB PEDIATRIC CLINICAL TRIALS IN ATOPIC DERMATITIS (AD) — A POOLED ANALYSIS. Annals of Allergy, Asthma & Immunology, 127(5), S16-S17.
Simpson E, Cork M, Arkwright P, Deleuran M, Chen Z, Rodriguez Marco A, Cyr S & Harel S (2021) P193 DUPILUMAB DECREASES TOTAL AND ALLERGEN-SPECIFIC IGE IN ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS (AD). Annals of Allergy, Asthma & Immunology, 127(5), S54-S55.
Thyssen J, Silverberg J, Cork M, Taieb A, Malhotra B, Johnson S, Fostvedt L, Feeney C & Biswas P (2021) P190 ABROCITINIB EFFICACY AND SAFETY BY BODY WEIGHT: POOLED ANALYSIS OF 3 RANDOMIZED CLINICAL TRIALS. Annals of Allergy, Asthma & Immunology, 127(5), S53-S54.
Simpson EL, Paller AS, Siegfried EC, Thaçi D, Wollenberg A, Cork MJ, Marcoux D, Huang R, Chen Z, Rossi AB , Shumel B et al (2021) Dupilumab demonstrates rapid and consistent improvement in extent and signs of atopic dermatitis across all anatomical regions in pediatric patients 6 years of age and older. Dermatology and Therapy, 11, 1643-1656. View this article in WRRO
Silverberg JI, Simpson EL, Guttman-Yassky E, Cork MJ, de Bruin-Weller M, Yosipovitch G, Eckert L, Chen Z, Ardeleanu M, Shumel B , Hultsch T et al (2021) Dupilumab significantly modulates pain and discomfort in patients with atopic dermatitis : a post hoc analysis of 5 randomized clinical trials. Dermatitis, 32(1S), S81-S91.
Spergel JM, Blaiss MS, Lio P, Kessel A, Cantrell WC, Takiya L, Werth JL, O'Connell MA, Zang C & Cork MJ (2021) Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis and other atopic comorbidities. Allergy and Asthma Proceedings, 42(5), 425-431.
Paller AS, Wollenberg A, Siegfried E, Thaçi D, Cork MJ, Arkwright PD, Gooderham M, Sun X, O’Malley JT, Khokhar FA , Vakil J et al (2021) Laboratory safety of dupilumab in patients aged 6–11 years with severe atopic dermatitis : results from a phase III clinical trial. Pediatric Drugs, 23(5), 515-527.
Lin WC, Byers RA, Li W, Danby SG, Cork MJ & Matcher SJ (2021) Imaging striae distensae : a comparison between PS-OCT and digital dermoscopy. Biomedical Optics Express, 12(6), 3296-3311. View this article in WRRO
Paller A, Cork MJ, Marcoux D, Zhang H, Chuang C, Zhang A & Chao J (2021) 484 Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs and symptoms and quality of life (QoL) in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial. Journal of Investigative Dermatology, 141(5), s84.
O’Kane D, Davis L, Ardern-Jones M, Laws P, Shaw L, Cork M, Velangi S, Cooper HL, Hudson R, Smith AB & Rout R (2021) Treatment outcomes of patients with atopic dermatitis (AD) treated with dupilumab through the early access to medicines scheme (EAMS) in the UK. Ulster Medical Journal, 90(2), 70-76.
Ring J, Worm M, Wollenberg A, Thyssen JP, Jakob T, Klimek L, Bangert C, Barbarot S, Bieber T, de Bruin-Weller MS , Chernyshov PV et al (2021) Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts.. Journal of the European Academy of Dermatology and Venereology. View this article in WRRO
Stamatas GN, Bensaci J, Greugny E, Kaur S, Wang H, Dizon MV, Cork MJ, Friedman AJ & Oddos T (2021) A predictive self-organizing multicellular computational model of infant skin permeability to topically applied substances. Journal of Investigative Dermatology.
Thyssen JP, Vestergaard C, Barbarot S, de Bruin‐Weller MS, Bieber T, Taieb A, Seneschal J, Cork MJ, Paul C, Flohr C , Weidinger S et al (2021) European Task Force on Atopic Dermatitis (ETFAD): position on vaccination of adult patients with atopic dermatitis against COVID‐19 (SARS‐CoV‐2) being treated with systemic medication and biologics. Journal of the European Academy of Dermatology and Venereology. View this article in WRRO
Paller AS, Siegfried EC, Simpson EL, Cork MJ, Lockshin B, Kosloski MP, Kamal MA, Davis JD, Sun X, Pirozzi G , Graham NMH et al (2021) A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. Journal of the European Academy of Dermatology and Venereology, 35(2), 464-475. View this article in WRRO
Spergel J, Blaiss M, Lio P, Kessel A, Takiya L, Werth J, O'Connell M, Zang C & Cork M (2021) Efficacy and Safety of Crisaborole in Patients With Mild-to-Moderate Atopic Dermatitis With Comorbid Allergic Rhinitis or Asthma. Journal of Allergy and Clinical Immunology, 147(2), AB28-AB28.
McMichael A, Cork M, Teng J, Rojo R, Valdez H, Zhang F, Myers D, Chan G & DiBonaventura M (2021) Patient-Reported Outcomes (PROs) With Abrocitinib Treatment in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN Study. Journal of Allergy and Clinical Immunology, 147(2), ab156.
Abuabara K, Nicholls SG, Langan SM, Guttman-Yassky E, Reynolds NJ, Paller AS, Brown SJ, Agner T, Aoki V, Bagot M , Barbarot S et al (2021) Priority research questions in atopic dermatitis: an International Eczema Council eDelphi consensus. British Journal of Dermatology.
Cork MJ, Lockshin B, Morren M-A, Etoh T, Chen Z, Rossi AB, Lu Y, Bansal A & Shabbir A (2020) Le dupilumab améliore les signes et symptômes de dermatite atopique érythrodermique chez des patients adultes et adolescents – analyse poolée de sous-groupes. Annales de Dermatologie et de Vénéréologie, 147(12), A362-A362.
Danby SG, Andrew P, Kay L, Pinnock A, Brown K & Cork MJ (2020) 16818 An investigation of the skin barrier restoring effects of a cream containing ceramides in a multivesicular emulsion in people with dry, eczema-prone, skin: The RESTORE study phase 2. Journal of the American Academy of Dermatology, 83(6), AB71-AB71.
Cork MJ, Lockshin B, Morren M-A, Etoh T, Chen Z, Rossi AB, Lu Y, Bansal A & Shabbir A (2020) 15413 Dupilumab improves signs and symptoms in adult and adolescent patients with erythrodermic atopic dermatitis: A pooled subgroup analysis. Journal of the American Academy of Dermatology, 83(6), AB39-AB39.
Wollenberg A, Christen‐Zäch S, Taieb A, Paul C, Thyssen JP, Bruin‐Weller M, Vestergaard C, Seneschal J, Werfel T, Cork MJ , Kunz B et al (2020) ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. Journal of the European Academy of Dermatology and Venereology.
Blaiss M, Cork M, Lio P, Kessel A, Takiya L, Werth J, O'Connell M, Zang C & Spergel J (2020) P302 EFFICACY OF CRISABOROLE IN PATIENTS WITH MILD-TO-MODERATE ATOPIC DERMATITIS WITH AND WITHOUT FOOD ALLERGIES. Annals of Allergy, Asthma & Immunology, 125(5), S40-S41.
Spergel J, Blaiss M, Lio P, Kessel A, Takiya L, Werth J, O'Connell M, Zang C & Cork M (2020) P500 EFFICACY OF CRISABOROLE IN PATIENTS WITH MILD-TO-MODERATE ATOPIC DERMATITIS WITH AND WITHOUT COMORBID ALLERGIC RHINITIS. Annals of Allergy, Asthma & Immunology, 125(5), S46-S46.
Wollenberg A, Blauvelt A, Guttman‐Yassky E, Worm M, Lynde C, Lacour J, Spelman L, Katoh N, Saeki H, Poulin Y , Lesiak A et al (2020) Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2). British Journal of Dermatology.
Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Sun X, Chen Z, Akinlade B, Boklage S, Guillemin I, Kosloski MP , Kamal MA et al (2020) Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study. British Journal of Dermatology.
Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, Bieber T, Thyssen JP, Yosipovitch G, Flohr C , Magnolo N et al (2020) Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet, 396(10246), 255-266. View this article in WRRO
Danby SG, Draelos ZD, Gold LFS, Cha A, Vlahos B, Aikman L, Sanders P, Wu-Linhares D & Cork MJ (2020) Vehicles for atopic dermatitis therapies: more than just a placebo. Journal of Dermatological Treatment. View this article in WRRO
Danby SG, Andrew PV, Brown K, Chittock J, Kay LJ & Cork MJ (2020) An investigation of the skin barrier restoring effects of a cream and lotion containing ceramides in a multi-vesicular emulsion in people with dry, eczema-prone, skin: The RESTORE study phase 1. Dermatology and Therapy. View this article in WRRO
Paller AS, Siegfried EC, Thaçi D, Wollenberg A, Cork MJ, Arkwright PD, Gooderham M, Beck LA, Boguniewicz M, Sher L , Weisman J et al (2020) Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. Journal of the American Academy of Dermatology. View this article in WRRO
de Bruin-Weller M, Simpson EL, Cork M, Chen Z, Msihid J, Taniou C, Eckert L, Gadkari A & Bégo-Le Bagousse G (2020) Dupilumab reduces absenteeism in patients with moderate to severe atopic dermatitis: Pooled results from the LIBERTY AD SOLO clinical trials. Journal of the American Academy of Dermatology.
Wollenberg A, Flohr C, Simon D, Cork MJ, Thyssen JP, Bieber T, de Bruin-Weller MS, Weidinger S, Deleuran M, Taieb A , Paul C et al (2020) European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis. Journal of the European Academy of Dermatology and Venereology. View this article in WRRO
Chalmers JR, Haines RH, Bradshaw LE, Montgomery AA, Thomas KS, Brown SJ, Ridd MJ, Lawton S, Simpson EL, Cork MJ , Sach TH et al (2020) Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. The Lancet, 395(10228), 962-972.
Carr AN, DeWitt T, Cork MJ, Eichenfield LF, Fölster‐Holst R, Hohl D, Lane AT, Paller A, Pickering L, Taieb A , Cui TY et al (2020) Diaper dermatitis prevalence and severity : global perspective on the impact of caregiver behavior. Pediatric Dermatology, 37(1), 130-136. View this article in WRRO
Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Hultsch T, Davis JD, Zhang Y, Zhu X, Chen Z, Li M , Ardeleanu M et al (2020) 一项关于 dupilumab 治疗湿疹青少年患者的研究. British Journal of Dermatology, 182(1), e47-e47.
Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Hultsch T, Davis JD, Zhang Y, Zhu X, Chen Z, Li M , Ardeleanu M et al (2020) A study of dupilumab in the treatment of adolescents with eczema. British Journal of Dermatology, 182(1), e30-e30.
Simpson JK, Martinez‐Queipo M, Onoufriadis A, Tso S, Glass E, Liu L, Higashino T, Scott W, Tierney C, Simpson MA , Desomchoke R et al (2020) Genotype–phenotype correlation in a large English cohort of patients with autosomal recessive ichthyosis. British Journal of Dermatology, 182(3), 729-737.
Jabbar-Lopez ZK, Gurung N, Greenblatt D, Briley A, Chalmers JR, Thomas KS, Frost T, Kezic S, Common JEA, Kong HH , Segre JA et al (2019) Protocol for an outcome assessor-blinded pilot randomised controlled trial of an ion-exchange water softener for the prevention of atopic eczema in neonates, with an embedded mechanistic study : the softened water for eczema prevention (SOFTER) trial. BMJ Open, 9(8). View this article in WRRO
Vestergaard C, Wollenberg A, Barbarot S, Christen‐Zaech S, Deleuran M, Spuls P, Flohr C, Trzeciak M, von Kobyletzki L, Seneschal J , Paul C et al (2019) European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. Journal of the European Academy of Dermatology and Venereology, 33(9), 1644-1659.
Cork MJ, Eckert L, Simpson EL, Armstrong A, Barbarot S, Puig L, Girolomoni G, de Bruin-Weller M, Wollenberg A, Kataoka Y , Remitz A et al (2019) Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. Journal of Dermatological Treatment. View this article in WRRO
Berth‐Jones J, Exton LS, Ladoyanni E, Mohd Mustapa MF, Tebbs VM, Yesudian PD, Levell NJ, McHenry PM, Leslie TA, Wakelin S , Hunasehally RYP et al (2019) British Association of Dermatologists guidelines for the safe and effective prescribing of oral ciclosporin in dermatology 2018. British Journal of Dermatology, 180(6), 1312-1338.
Thyssen JP, Bruin‐Weller MS, Paller AS, Leshem YA, Vestergaard C, Deleuran M, Drucker AM, Foelster‐Holst R, Hoffmann CT, Eyerich K , Taieb A et al (2019) Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion. Journal of the European Academy of Dermatology and Venereology. View this article in WRRO
Leshem YA, Bissonnette R, Paul C, Silverberg JI, Irvine AD, Paller AS, Cork MJ & Guttman‐Yassky E (2019) Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey‐based position statement. Journal of the European Academy of Dermatology and Venereology, 33(5), 807-815. View this article in WRRO
Akinlade B, Guttman‐Yassky E, de Bruin‐Weller M, Simpson EL, Blauvelt A, Cork MJ, Prens E, Asbell P, Akpek E, Corren J , Bachert C et al (2019) Conjunctivitis in dupilumab clinical trials. British Journal of Dermatology. View this article in WRRO
McPherson T, Exton LS, Biswas S, Creamer D, Dziewulski P, Newell L, Tabor KL, Wali GN, Walker G, Walker R , Walker S et al (2019) British Association of Dermatologists' guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in children and young people, 2018. British Journal of Dermatology, 181(1), 37-54.
Simpson EL, Reynolds NJ, Flohr C, Paller AS, Silverberg JI, Cork MJ, Guttman-Yassky E & Irvine AD (2018) Response to “Comment on: ‘When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council’”. Journal of the American Academy of Dermatology, 79(2), e25-e26. View this article in WRRO
Liu Q, Zhang Y, Danby SG, Cork M & Stamatas G (2018) Infant Skin Barrier, Structure, and Enzymatic Activity Differ from Those of Adult in an East Asian Cohort. BioMed Research International, 2018. View this article in WRRO
de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, Zhang Q, Akinlade B, Gadkari A, Eckert L , Hultsch T et al (2018) Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t. British Journal of Dermatology, 178(5), e366-e366.
de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork M, Radin A, Zhang Q, Akinlade B, Gadkari A, Eckert L , Hultsch T et al (2018) 杜匹鲁单抗结合伴随性局部皮质类固醇治疗对环孢素A应答不充分或不耐受或者在医学上不建议采用环孢素A治疗的过敏性皮肤炎成人患者:安慰剂对照随机阶段III临床试验(LIBERTY AD CAFÉ). British Journal of Dermatology, 178(5), e385-e385.
de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork M, Radin A, Zhang Q, Akinlade B, Gadkari A, Eckert L , Hultsch T et al (2018) Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). British Journal of Dermatology, 178(5), 1083-1101. View this article in WRRO
Lewis FM, Tatnall FM, Velangi SS, Bunker CB, Kumar A, Brackenbury F, Mohd Mustapa MF, Exton LS, McHenry PM, Leslie TA , Wakelin S et al (2018) British Association of Dermatologists guidelines for the management of lichen sclerosus, 2018. British Journal of Dermatology, 178(4), 839-853.
Byers RA, Maiti R, Danby SG, Pang EJ, Mitchell B, Carré MJ, Lewis R, Cork MJ & Matcher SJ (2018) Sub-clinical assessment of atopic dermatitis severity using angiographic optical coherence tomography. Biomedical Optics Express, 9(4), 2001-2001. View this article in WRRO
Irvine AD, Jones AP, Beattie P, Baron S, Browne F, Ashoor F, O'Neill L, Rosala-Hallas A, Sach T, Spowart C , Taams L et al (2018) A randomized controlled trial protocol assessing the effectiveness, safety and cost-effectiveness of methotrexate vs. ciclosporin in the treatment of severe atopic eczema in children: the TREatment of severe Atopic eczema Trial (TREAT). British Journal of Dermatology, 179(6), 1297-1306.
Danby SG, Brown K, Wigley A, Chittock J, Pyae P, Flohr C & Cork M (2018) The Effect of Water Hardness on Surfactant Deposition after Washing and Subsequent Skin Irritation in Atopic Dermatitis Patients and Healthy Control Subjects. Journal of Investigative Dermatology, 138(1), 68-77. View this article in WRRO
Thaçi D, Wollenberg A, Remitz A, Cork MJ, Bieber T, Beissert S, Chen Z, Gadkari A, Eckert L, Hultsch T & Ardeleanu M (2017) Le dupilumab lors de dermatite atopique modérée à sévère : résultats groupés de deux études randomisées de phase III (SOLO 1 et 2). Annales de Dermatologie et de Vénéréologie, 144(12), S266-S267.
De Bruin-Weller M, Gadkari A, Simpson E, Cork M, Puig L, Girolomoni G, Wollenberg A, Chen Z, Radin A, Shumel B , Ardeleanu M et al (2017) P479 Dupilumab improves patient-reported outcomes in atopic dermatitis patients inadequately controlled, intolerant, or inadvisable for cyclosporine-A. Annals of Allergy, Asthma & Immunology, 119(5), S94-S95.
Harman KE, Brown D, Exton LS, Groves RW, Hampton PJ, Mohd Mustapa MF, Setterfield JF, Yesudian PD, McHenry PM, Gibbon K , Buckley DA et al (2017) British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017. British Journal of Dermatology, 177(5), 1170-1201.
Simpson EL, Bruin-Weller M, Flohr C, Ardern-Jones MR, Barbarot S, Deleuran M, Bieber T, Vestergaard C, Brown SJ, Cork MJ , Drucker AM et al (2017) When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. Journal of the American Academy of Dermatology, 77(4), 623-633. View this article in WRRO
Cork MJ & Danby SG (2017) The British Skin Foundation: 20 years of supporting dermatology research. British Journal of Dermatology, 177(3), 608-609.
Chalmers JR, Haines RH, Mitchell EJ, Thomas KS, Brown SJ, Ridd M, Lawton S, Simpson EL, Cork MJ, Sach TH , Bradshaw LE et al (2017) Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (The BEEP trial): protocol for a randomised controlled trial.. Trials, 18(1), 343-343. View this article in WRRO
Koh MJ-A, Giam YC, Liew HM, Foong AY-W, Chong JH, Wong SMY, Tang MBY, Ho MSL, Tan LS, Mason JM & Cork MJ (2017) Erratum to: Comparison of the Simple Patient-Centric Atopic Dermatitis Scoring System PEST with SCORAD in Young Children Using a Ceramide Dominant Therapeutic Moisturizer. Dermatol Ther (Heidelb).
Christodoulides P, Hirata Y, Dominguez-Huttinger E, Danby SG, Cork M, Williams HC, Aihara K & Tanaka R (2017) Computational design of treatment strategies for proactive therapy on atopic dermatitis using optimal control theory. Royal Society of London. Philosophical Transactions A. Mathematical, Physical and Engineering Sciences, 375(2096). View this article in WRRO
Koh MJ-A, Giam YC, Liew HM, Foong AY-W, Chong JH, Wong SMY, Tang MBY, Ho MSL, Tan LS, Mason JM & Cork MJ (2017) Comparison of the Simple Patient-Centric Atopic Dermatitis Scoring System PEST with SCORAD in Young Children Using a Ceramide Dominant Therapeutic Moisturizer. Dermatology and Therapy. View this article in WRRO
Smith CH, Jabbar‐Lopez ZK, Yiu ZZ, Bale T, Burden AD, Coates LC, Cruickshank M, Hadoke T, MacMahon E, Murphy R , Nelson‐Piercy C et al (2017) British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. British Journal of Dermatology, 177(3), 628-636.
Danby SG, Wigley A, Cork MJ & Cork MJ (2017) Biologic Treatments for Atopic Eczema: Anti IL-4 and IL-13 biologics. Exchange: National Eczema Society Members' Magazine(163), 11-18. View this article in WRRO
Johnston GA, Exton LS, Mohd Mustapa MF, Slack JA, Coulson IH, English JSC, Bourke JF, McHenry PM, Gibbon K, Buckley DA , Leslie TA et al (2017) British Association of Dermatologists’ guidelines for the management of contact dermatitis 2017. British Journal of Dermatology, 176(2), 317-329.
Berker D, McGregor JM, Mohd Mustapa MF, Exton LS, Hughes BR, McHenry PM, Gibbon K, Buckley DA, Nasr I, Duarte Williamson CE , Swale VJ et al (2017) British Association of Dermatologists’ guidelines for the care of patients with actinic keratosis 2017. British Journal of Dermatology, 176(1), 20-43.
Mohd Mustapa MF, Exton LS, Bell HK, Ormerod AD, Hughes JR, Levell NJ, Smith CH, McHenry PM, Gibbon K, Buckley DA , Leslie TA et al (2017) Updated guidance for writing a British Association of Dermatologists clinical guideline: the adoption of the GRADE methodology 2016. British Journal of Dermatology, 176(1), 44-51.
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP , Kingo K et al (2016) Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. New England Journal of Medicine, 375, 2335-2348. View this article in WRRO
Albenali LH, Danby S, Moustafa M, Brown K, Chittock J, Shackley F & Cork MJ (2016) Vitamin D and antimicrobial peptide levels in patients with atopic dermatitis and atopic dermatitis complicated by eczema herpeticum: A pilot study. Journal of Allergy and Clinical Immunology, 138(5), 1715-1719.e4. View this article in WRRO
Danby SG, Chalmers J, Brown K, Williams HC & Cork MJ (2016) A functional mechanistic study of the effect of emollients on the structure and function of the skin barrier. British Journal of Dermatology, 175(5), 1011-1019. View this article in WRRO
Chittock J, Cooke A, Lavender T, Brown K, Wigley A, Victor S, Cork MJ & Danby SG (2016) Development of stratum corneum chymotrypsin-like protease activity and natural moisturizing factors from birth to 4 weeks of age compared with adults. British Journal of Dermatology, 175(4), 713-720. View this article in WRRO
Warren RB, Weatherhead SC, Smith CH, Exton LS, Mohd Mustapa MF, Kirby B, Yesudian PD, McHenry PM, Gibbon K, Buckley DA , Nasr I et al (2016) British Association of Dermatologists’ guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. British Journal of Dermatology, 175(1), 23-44.
Danby SG, Brown K, Higgs-Bayliss T, Chittock J, Albenali L & Cork M (2016) The Effect of an Emollient Containing Urea, Ceramide NP, and Lactate on Skin Barrier Structure and Function in Older People with Dry Skin. Skin Pharmacology and Physiology, 29(3), 135-147. View this article in WRRO
Blume-Peytavi U, Lavender T, Jenerowicz D, Ryumina I, Stalder J-F, Torrelo A & Cork MJ (2016) Recommendations from a European Roundtable Meeting on Best Practice Healthy Infant Skin Care. Pediatric Dermatology, 33(3), 311-321. View this article in WRRO
Cooke A, Cork M, Victor S, Campbell M, Danby S, Chittock J & Lavender T (2016) Olive Oil, Sunflower Oil or no Oil for Baby Dry Skin or Massage: A Pilot, Assessor-blinded, Randomized Controlled Trial (the Oil in Baby SkincaRE [OBSeRvE] Study). Acta Dermato Venereologica, 96(3), 323-330.
Luger T, Boguniewicz M, Carr W, Cork M, Deleuran M, Eichenfield L, Eigenmann P, Fölster-Holst R, Gelmetti C, Gollnick H , Hamelmann E et al (2015) Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants. Pediatric Allergy and Immunology, 26(4), 306-315. View this article in WRRO
Chittock J, Brown K, Cork M & Danby S (2015) Comparing the Effect of a Twice-weekly Tacrolimus and Betamethasone Valerate Dose on the Subclinical Epidermal Barrier Defect in Atopic Dermatitis. Acta Dermato Venereologica, 95(6), 653-658.
Cowdell F, Jadotte JT, Ersser SJ, Danby SG, Walton S, Lawton S, Roberts A, Gardiner E, Ware F & Cork MJ (2014) Hygiene and emollient interventions for maintaining skin integrity in older people in hospital and residential care settings. Cochrane Database of Systematic Reviews, 2014(12), 1-16.
Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WHI, Brown SJ, Chen Z, Chen Y & Williams HC (2014) Wzmocnienie bariery skórnej środkami zmiękczającymi od urodzenia skutecznie zapobiega atopowemu zapaleniu skóry. Alergologia Polska - Polish Journal of Allergology, 1(4), T33-T41.
Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WHI, Brown SJ, Chen Z, Chen Y & Williams HC (2014) Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology, 134(4), 818-823.
Danby SG, Chittock J, Brown K, Albenali LH & Cork MJ (2014) The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis.. Br J Dermatol, 170(4), 914-921.
Cork MJ, Mason AR, Mason J, Dooley G & Hancock H (2013) Topical Treatments for Chronic Plaque Psoriasis. Journal of the American Academy of Dermatology(In Press).
Mason A, Mason J, Cork M, Hancock H & Dooley G (2013) Topical treatments for chronic plaque psoriasis: An abridged Cochrane Systematic Review. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 69(5), 799-807.
Mason AR, Mason JM, Cork MJ, Hancock H & Dooley G (2013) Topical treatments for chronic plaque psoriasis of the scalp: a systematic review. BRITISH JOURNAL OF DERMATOLOGY, 169(3), 519-527.
Moncrieff G, Cork M, Lawton S, Kokiet S, Daly C & Clark C (2013) Use of emollients in dry-skin conditions: Consensus statement. Clinical and Experimental Dermatology, 38(3), 231-238.
Mason AR, Mason J, Cork MJ, Dooley G & Hancock H (2013) Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev..
Danby SG & Cork MJ (2013) The effects of pimecrolimus on the innate immune response in atopic dermatitis.. Br J Dermatol, 168(2), 235-236.
Lu Z, Boadi J, Danby S, Cork M & Matcher SJ (2013) Optical coherence tomography demonstrates differential epidermal thinning of human forearm volar skin after 2 weeks application of a topical corticosteroid vs a non-steroidal anti-inflammatory alternative. Progress in Biomedical Optics and Imaging - Proceedings of SPIE, 8565.
Mason JM, Carr J, Buckley C, Hewitt S, Berry P, Taylor J & Cork MJ (2013) Improved emollient use reduces atopic eczema symptoms and is cost neutral in infants: before-and-after evaluation of a multifaceted educational support programme.. BMC Dermatol, 13, 7. View this article in WRRO
Lavender T, Bedwell C, Roberts SA, Carter L-A, Hart A, Turner MA & Cork MJ (2013) Randomized, Controlled Trial Evaluating a Baby Wash Product on Skin Barrier Function in Healthy, Term Neonates. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing. View this article in WRRO
Danby SG, AlEnezi T, Sultan A, Lavender T, Chittock J, Brown K & Cork MJ (2013) Effect of olive and sunflower seed oil on the adult skin barrier: implications for neonatal skin care.. Pediatr Dermatol, 30(1), 42-50.
Lavender T, Furber C, Campbell M, Victor S, Roberts I, Bedwell C & Cork MJ (2012) Effect on skin hydration of using baby wipes to clean the napkin area of newborn babies: Assessor-blinded randomised controlled equivalence trial. BMC Pediatrics, 12. View this article in WRRO
Tsoi LC, Spain SL, Barker JNWN, Trembath RC, Knight J, Ellinghaus E, Schreiber S, Stuart PE, Tejasvi T, Gudjonsson JE , Voorhees JJ et al (2012) Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nature Genetics. View this article in WRRO
Furber C, Bedwell C, Campbell M, Cork M, Jones C, Rowland L & Lavender T (2012) The Challenges and Realties of Diaper Area Cleansing for Parents. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 41(6).
Knight J, Spain SL, Capon F, Hayday A, Nestle FO, Clop A, Barker JN, Weale ME & Trembath RC (2012) Conditional analysis identifies three novel major histocompatibility complex loci associated with psoriasis. Human Molecular Genetics, 21(23), 5185-5192.
Bieber T, Cork M & Reitamo S (2012) Atopic dermatitis: A candidate for disease-modifying strategy. Allergy: European Journal of Allergy and Clinical Immunology.
Cork MJ (2011) Patient education about topical treatments. BRITISH JOURNAL OF DERMATOLOGY, 165(6), 1159-1160.
Moustafa M, Holden CR, Athavale P, Cork MJ, Messenger AG & Gawkrodger DJ (2011) Patch testing is a useful investigation in children with eczema. CONTACT DERMATITIS, 65(4), 208-212.
Lavender T, Furber C, Cork M, Campbell M & Victor S (2011) Baby skin care research programme: assessor-blinded randomised controlled trial comparing impregnated cleansing wipes with water in infants. Archives of Disease in Childhood - Fetal and Neonatal Edition, 96(Supplement 1), Fa43-Fa43.
Cork MJ & Danby S (2011) Aqueous cream damages the skin barrier.. Br J Dermatol, 164(6), 1179-1180.
Lavender T, Bedwell C, O'Brien E, Cork MJ, Turner M & Hart A (2011) Infant skin-cleansing product versus water: A pilot randomized, assessor-blinded controlled trial. BMC PEDIATR, 11. View this article in WRRO
Danby SG, Al-Enezi T, Sultan A, Chittock J, Kennedy K & Cork MJ (2011) The effect of aqueous cream BP on the skin barrier in volunteers with a previous history of atopic dermatitis.. Br J Dermatol, 165(2), 329-334.
Moustafa M, Holden CR, Athavale P, Cork MJ, Messenger AG & Gawkrodger DJ (2011) Patch testing is a useful investigation in children with eczema.. Contact Dermatitis, 65(4), 208-212.
Vasilopoulos Y, Sagoo GS, Cork MJ, Walters K & Tazi-Ahnini R (2011) HLA-C, CSTA and DS12346 susceptibility alleles confer over 100-fold increased risk of developing psoriasis: evidence of gene interaction.. J Hum Genet, 56(6), 423-427.
Bangert C, Strober BE, Cork M, Ortonne JP, Luger T, Bieber T, Ferguson A, Ecker RC, Kopp T, Weise-Riccardi S , Guettner A et al (2011) Clinical and Cytological Effects of Pimecrolimus Cream 1% after Resolution of Active Atopic Dermatitis Lesions by Topical Corticosteroids: A Randomized Controlled Trial. DERMATOLOGY, 222(1), 36-48.
Cooke A, Cork MJ, Danby S & Lavender T (2011) Use of oil for baby skincare: A survey of UK maternity and neonatal units. British Journal of Midwifery, 19(6), 354-362.
Vasilopoulos Y, Sharaf N, di Giovine F, Simon M, Cork MJ, Duff GW & Tazi-Ahnini R (2011) The 3'-UTR AACCins5874 in the stratum corneum chymotryptic enzyme gene (SCCE/KLK7), associated with atopic dermatitis; causes an increased mRNA expression without altering its stability.. J Dermatol Sci, 61(2), 131-133.
Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2 , Strange A, Capon F, Spencer CCA, Knight J, Weale ME, Allen MH, Barton A, Band G, Bellenguez C , Bergboer JGM et al (2010) A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1.. Nat Genet, 42(11), 985-990.
Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M, Guy RH, Macgowan AL, Tazi-Ahnini R & Ward SJ (2009) Epidermal barrier dysfunction in atopic dermatitis.. J Invest Dermatol, 129(8), 1892-1908.
Cork MJ & Danby S (2009) Skin barrier breakdown: a renaissance in emollient therapy.. Br J Nurs, 18(14), 872-877.
Blume-Peytavi U, Cork MJ, Faergemann J, Szczapa J, Vanaclocha F & Gelmetti C (2009) Bathing and cleansing in newborns from day 1 to first year of life: recommendations from a European round table meeting. J EUR ACAD DERMATOL, 23(7), 751-759.
Lavender T, Bedwell C, Tsekiri-O'Brien E, Hart A, Turner M & Cork M (2009) A qualitative study exploring women's and health professionals' views of newborn bathing practices. Evidence Based Midwifery, 7(4), 112-121.
Mason AR, Mason J, Cork M, Dooley G & Edwards G (2009) Topical treatments for chronic plaque psoriasis. COCHRANE DB SYST REV(2).
Tazi-Ahnini R, McDonagh AJG, Wengraf DA, Lovewell TRJ, Vasilopoulos Y, Messenger AG, Cork MJ & Gawkrodger DJ (2008) The autoimmune regulator gene (AIRE) is strongly associated with vitiligo.. Br J Dermatol, 159(3), 591-596.
Vasilopoulos Y, Walters K, Cork MJ, Duff GW, Sagoo GS & Tazi-Ahnini R (2008) Association analysis of the skin barrier gene cystatin A at the PSORS5 locus in psoriatic patients: evidence for interaction between PSORS1 and PSORS5.. Eur J Hum Genet, 16(8), 1002-1009. View this article in WRRO
Cork MJ, Varghese J, Sultan A, Guy R, Lane M, AlEnezi T, Hadgraft J & Ward SJ (2008) Therapeutic Implications of the Differential Effects of Topical Corticosteroids and Calcineurin Inhibitors on the Skin Barrier. Dermatitis, 19(4), 218-238.
Simon M, Tazi-Ahnini R, Jonca N, Caubet C, Cork MJ & Serre G (2008) Alterations in the desquamation-related proteolytic cleavage of corneodesmosin and other corneodesmosomal proteins in psoriatic lesional epidermis.. Br J Dermatol, 159(1), 77-85.
Wengraf DA, McDonagh AJG, Lovewell TRJ, Vasilopoulos Y, Macdonald-Hull SP, Cork MJ, Messenger AG & Tazi-Ahnini R (2008) Genetic analysis of autoimmune regulator haplotypes in alopecia areata.. Tissue Antigens, 71(3), 206-212.
Cork MJ, Danby S, Vasilopoulos Y, Moustafa M, MacGowan A, Varghese J, Duff GW, Tazi-Ahnini R & Ward SJ (2008) Gene-environment interactions in atopic dermatitis. Drug Discovery Today: Disease Mechanisms, 5(1).
Vasilopoulos Y, Cork MJ, Teare D, Marinou I, Ward SJ, Duff GW & Tazi-Ahnini R (2007) A nonsynonymous substitution of cystatin A, a cysteine protease inhibitor of house dust mite protease, leads to decreased mRNA stability and shows a significant association with atopic dermatitis.. Allergy, 62(5), 514-519.
Langley RGB, Luger TA, Cork MJ, Schneider D & Paul C (2007) An update on the safety and tolerability of pimecrolimus cream 1%: Evidence from clinical trials and post-marketing surveillance. DERMATOLOGY, 215, 27-44.
Kemp EH, McDonagh AJG, Wengraf DA, Messenger AG, Gawkrodger DJ, Cork MJ & Tazi-Ahnini R (2006) The non-synonymous C1858T substitution in the PTPN22 gene is associated with susceptibility to the severe forms of alopecia areata.. Hum Immunol, 67(7), 535-539.
Cork MJ, Robinson DA, Vasilopoulos Y, Ferguson A, Moustafa M, MacGowan A, Duff GW, Ward SJ & Tazi-Ahnini R (2006) New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions.. J Allergy Clin Immunol, 118(1), 3-21.
Carlisle J, Shickle D, Cork M & McDonagh A (2006) Concerns over confidentiality may deter adolescents from consulting their doctors. A qualitative exploration.. J Med Ethics, 32(3), 133-137.
Chen HM, Wilkins LM, Aziz N, Cannings C, Wyllie DH, Bingle C, Rogus J, Beck JD, Offenbacher S, Cork MJ , Rafie-Kolpin M et al (2006) Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context. HUM MOL GENET, 15(4), 519-529.
Mee JB, Cork MJ, di Giovine FS, Duff GW & Groves RW (2006) Interleukin-1: a key inflammatory mediator in psoriasis?. Cytokine, 33(2), 72-78.
Paul C, Cork M, Rossi AB, Papp KA, Barbier N & de Prost Y (2006) Safety and tolerability of 1% pimecrolimus cream among infants: Experience with 1133 patients treated for up to 2 years. PEDIATRICS, 117(1), E118-E128.
Hengge UR, Ruzicka T, Schwartz RA & Cork MJ (2006) Adverse effects of topical glucocorticosteroids. J AM ACAD DERMATOL, 54(1), 1-15.
Cork MJ, Robinson D, Vasilopoulos Y, Ferguson A, Moustafa M, Mac Gowan A, Ward SJ & Tazi-Ahnini R (2005) Predisposition to sensitive skin and atopic eczema.. Community Pract, 78(12), 440-442.
Stevens KJ, Brazier JE, McKenna SP, Doward LC & Cork MJ (2005) The development of a preference-based measure of health in children with atopic dermatitis.. Br J Dermatol, 153(2), 372-377.
STRAUSS RM, FERGUSON AD, RITTEY CDC & CORK MJ (2005) MICROCEPHALY-LYMPHOEDEMA-CHORIORETINAL-DYSPLASIA SYNDROME WITH ATRIAL SEPTAL DEFECT. Pediatric Dermatology, 22(4), 373-374.
Lench N, Iles MM, Mackay I, Patel R, Sagoo GS, Ward SJ, Dechairo B, Olavesen M, Carey A, Duff GW , Cork MJ et al (2005) Single-point haplotype scores telomeric to human leukocyte antigen-C give a high susceptibility major histocompatibility complex haplotype for psoriasis in a Caucasian population.. J Invest Dermatol, 124(3), 545-552.
Bieber T, Cork M, Ellis C, Girolomoni G, Groves R, Langley R, Luger T, Meurer M, Murrell D, Orlow S , Paller A et al (2005) Consensus statement on the safety profile of topical calcineurin inhibitors. DERMATOLOGY, 211(2), 77-78.
Sagoo GS, Cork MJ, Patel R & Tazi-Ahnini R (2004) Genome-wide studies of psoriasis susceptibility loci: a review.. J Dermatol Sci, 35(3), 171-179.
Vasilopoulos Y, Cork MJ, Murphy R, Williams HC, Robinson DA, Duff GW, Ward SJ & Tazi-Ahnini R (2004) Genetic association between an AACC insertion in the 3'UTR of the stratum corneum chymotryptic enzyme gene and atopic dermatitis.. J Invest Dermatol, 123(1), 62-66.
Bowling DJ & Cork DMJ (2003) Severe pruritus in a patient with urticaria pigmentosa treated with topical 5% urea and 3% polidocanol cream. Journal of Dermatological Treatment, 14(3), 190-191.
Cork MJ, Britton J, Butler L, Young S, Murphy R & Keohane SG (2003) Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse.. Br J Dermatol, 149(3), 582-589.
Tazi-Ahnini R, Cork MJ, Wengraf D, Wilson AG, Gawkrodger DJ, Birch MP, Messenger AG & McDonagh AJG (2003) Notch4, a non-HLA gene in the MHC is strongly associated with the most severe form of alopecia areata.. Hum Genet, 112(4), 400-403.
Goustas P, Cork MJ & Higson D (2003) Eumovate (clobetasone butyrate 0.05%) cream: a review of clinical efficacy and safety.. The Journal of dermatological treatment, 14(2), 71-85.
Cork MJ, Timmins J, Holden C, Carr J, Berry V, Tazi-Ahnini R & Ward SJ (2003) An audit of adverse drug reactions to aqueous cream in children with atopic eczema. Pharmaceutical Journal, 271(7277), 747-748.
Tazi-Ahnini R, Cork MJ, Gawkrodger DJ, Birch MP, Wengraf D, McDonagh AJG & Messenger AG (2002) Role of the autoimmune regulator (AIRE) gene in alopecia areata: strong association of a potentially functional AIRE polymorphism with alopecia universalis.. Tissue Antigens, 60(6), 489-495.
Tazi-Ahnini R, Cork MJ, Gawkrodger D, Wengraf D, Messenger AG & McDonagh AJG (2002) Role of the autoimmune regulator (AIRE) gene in alopecia areata: Strong association of a potentially functional AIRE polymorphism with alopecia universalis. J INVEST DERMATOL, 119(3), 719-719.
Henderson JK, Taylor HR, Bavik CO, Ward SJ, Cork MJ & Tazi-Ahnini R (2002) Tumour necrosis factor-alpha induced up-regulation of elafin and antileukoprotease enhances the skin barrier. J INVEST DERMATOL, 119(3), 729-729.
Chen M-H, Antoni L, Tazi-Ahnini R, Cork M, Ward SJ & Båvik CO (2002) Identification of known and novel genes whose expression is regulated by endogenous retinoic acid during early embryonic development of the mouse. Mechanisms of Development, 114(1-2), 205-212.
Mason J, Mason AR & Cork MJ (2002) Topical preparations for the treatment of psoriasis: a systematic review. BRIT J DERMATOL, 146(3), 351-364.
Tazi-Ahnini R, Cox A, McDonagh AJG, Nicklin MJH, di Giovine FS, Timms JM, Messenger AG, Dimitropoulou P, Duff GW & Cork MJ (2002) Genetic analysis of the interleukin-1 receptor antagonist and its homologue IL-1L1 in alopecia areata: strong severity association and possible gene interaction.. Eur J Immunogenet, 29(1), 25-30.
Tazi-Ahnini R, McDonagh A, Cox A, di Giovine F, Messenger A, Duff G & Cork M (2001) Genetic analysis of the interleukin-1 receptor antagonist and its homologue IL1-L1 in alopecia areata: Strong disease associations and possible gene interaction. J INVEST DERMATOL, 117(2), 431-431.
Tazi-Ahnini R, McDonagh AJ, Cox A, Messenger AG, Britton JE, Ward SJ, Båvik CO, Duff GW & Cork MJ (2001) Association analysis of IL1A and IL1B variants in alopecia areata.. Heredity (Edinb), 87(Pt 2), 215-219.
Tazi-Ahnini R, di Giovine FS, McDonagh AJG, Messenger AG, Amadou C, Cox A, Duff GW & Cork MJ (2000) Structure and polymorphism of the human gene for the interferon-induced p78 protein (MX1): evidence of association with alopecia areata in the Down syndrome region. Human Genetics, 106(6), 639-645.
Tazi-Ahnini R, di Giovine FS, McDonagh AJ, Messenger AG, Amadou C, Cox A, Duff GW & Cork MJ (2000) Structure and polymorphism of the human gene for the interferon-induced p78 protein (MX1): evidence of association with alopecia areata in the Down syndrome region.. Hum Genet, 106(6), 639-645.
Mason J, Mason AR & Cork MJ (2000) Topical preparations for the treatment of psoriasis: a systematic review. British Journal of Dermatology, 142(3), 351-364.
Ahnini RT, Camp NJ, Cork MJ, Mee JB, Keohane SG, Duff GW & Di Giovine FS (2000) Corrigendum: Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to psoriasis (Human Molecular Genetics (2000) 8 (1135-1140)). Human Molecular Genetics, 9(4), 659.
Harper JI, Ahmed I, Barclay G, Lacour M, Hoeger P, Cork MJ, Finlay AY, Wilson NJE, Graham-Brown RAC, Sowden JM , Beard AL et al (2000) Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. BRIT J DERMATOL, 142(1), 52-58.
Tazi-Ahnini R, di Giovine FS, Cox A, Keohane SG & Cork MJ (1999) Corneodesmosin (MHC S) gene in guttate psoriasis.. Lancet, 354(9178), 597.
Tazi Ahnini R, Camp NJ, Cork MJ, Mee JB, Keohane SG, Duff GW & di Giovine FS (1999) Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to psoriasis.. Hum Mol Genet, 8(6), 1135-1140.
Ahnini RT, Cork M, Camp N, Mee J, Keohane S, Duff G & di Giovine F (1999) Genetic association between MHC S gene and susceptibility to psoriasis. J INVEST DERMATOL, 112(4), 591-591.
Carter MJ, di Giovine FS, Sorrell JA, Wilson AG, Keohane S, Cork MJ, Sanders DS, Duff GW & Lobo AJ (1999) Genetic susceptibility and disease behaviour in Crohns disease: The role of tumour necrosis factor alpha gene promoter polymorphisms. GUT, 44, A29-A29.
Carter MJ, di Giovine FS, Sorrell JA, Wilson AG, Keohane S, Cork MJ, Sanders DS, Duff GW & Lobo AJ (1999) The tumor necrosis factor alpha gene promoter polymorphisms and Crohns disease: Study of genetic suscepibility and disease behavior. GASTROENTEROLOGY, 116(4), A678-A678.
Cockayne SE, Cork MJ & Gawkrodger DJ (1999) Treatment of psoriasis: day care vs. inpatient therapy. BRIT J DERMATOL, 140(2), 375-376.
Cork MJ (1999) Taking the itch out of eczema: How the careful use of emollients can break the itch-scratch cycle of atopic eczema. Asthma Journal, 4(3), 116-120.
Kemp EH, Ajjan RA, Waterman EA, Gawkrodger DJ, Cork MJ, Watson PF & Weetman AP (1999) Analysis of a microsatellite polymorphism of the cytotoxic T-lymphocyte antigen-4 gene in patients with vitiligo.. Br J Dermatol, 140(1), 73-78.
Humphrey KM, Cork MJ & Haycox A (1998) A retrospective cost-effectiveness analysis of the treatment of onychomycosis in general practice. BRIT J DERMATOL, 139(4), 660-664.
Mee JB & Cork MJ (1998) Vitamin D receptor polymorphism and calcipotriol response in patients with psoriasis. J INVEST DERMATOL, 110(3), 301-302.
Cork MJ (1997) The importance of skin barrier function. J DERMATOL TREAT, 8, S7-S13.
Cork MJ, Keohane SG, Gawkrodger DJ, Hancock BW, Sheridan E & Bleehen SS (1997) Cytokine dermatosis: Reactivation of eczema during interleukin-2 infusion. BRIT J DERMATOL, 136(4), 644-645.
Tarlow JK, Cork MJ, Clay FE, SchmittEgenolf M, Crane AM, Stierle C, Boehncke WH, Eiermann TH, Blakemore AIF, Bleehen SS , Sterry W et al (1997) Association between interleukin-1 receptor antagonist (IL-1ra) gene polymorphism and early and late-onset psoriasis. BRIT J DERMATOL, 136(1), 147-148.
Cork MJ, Crane AM & Duff GW (1996) Genetic control of cytokines. Cytokine gene polymorphisms in alopecia areata.. Dermatol Clin, 14(4), 671-678.
Clay FE, Cork MJ, Wilson AG, Crane AM, Lewis F, Harrington CI & Duff GW (1996) Promoter region polymorphism in the human TNF-alpha gene is not associated with lichen sclerosus.. Exp Dermatol, 5(4), 227-229.
BerthJones J, Finlay AY, Zaki I, Tan B, Goodyear H, LewisJones S, Cork MJ, Bleehen SS, Salek MS, Allen BR , Friedmann P et al (1996) Cyclosporine in severe childhood atopic dermatitis: A multicenter study. J AM ACAD DERMATOL, 34(6), 1016-1021.
Clay FE, Tarlow JK, Cork MJ, Cox A, Nicklin MJ & Duff GW (1996) Novel interleukin-1 receptor antagonist exon polymorphisms and their use in allele-specific mRNA assessment.. Hum Genet, 97(6), 723-726.
Clay FE, Tarlow JK, Cork MJ, Cox A, Nicklin MJH & Duff GW (1996) Novel interleukin-1 receptor antagonist exon polymorphisms and their use in allele-specific mRNA assessment. Human Genetics, 97(6), 723-726.
CORK MJ, DIGIOVINE FS, CRANE SA, MEE JB & DUFF GW (1995) NOVEL GENETIC ASSOCIATION OF AN IL-1-BETA GENE VARIATION AT-+3953, SUSCEPTIBILITY TO PSORIASIS AND IL-1-BETA PROTEIN-PRODUCTION. J INVEST DERMATOL, 105(3), 453-453.
KEOHANE SG & CORK MJ (1995) TREATMENT OF GROVERS-DISEASE WITH CALCIPOTRIOL (DOVONEX(R)). BRIT J DERMATOL, 132(5), 832-833.
Wilson AG, Clay FE, Crane AM, Cork MJ & Duff GW (1995) Comparative genetic association of human leukocyte antigen class II and tumor necrosis factor-alpha with dermatitis herpetiformis.. J Invest Dermatol, 104(5), 856-858.
Cork MJ, Tarlow JK, Clay FE, Crane A, Blakemore AI, McDonagh AJ, Messenger AG & Duff GW (1995) An allele of the interleukin-1 receptor antagonist as a genetic severity factor in alopecia areata.. J Invest Dermatol, 104(5 Suppl), 15S-16S.
Clay FE, Cork MJ, Tarlow JK, Blakemore AI, Harrington CI, Lewis F & Duff GW (1994) Interleukin 1 receptor antagonist gene polymorphism association with lichen sclerosus.. Hum Genet, 94(4), 407-410.
CLAY FE, CORK MJ, TARLOW JK, BLAKEMORE AIF, LEWIS F, HARRINGTON CI & DUFF GW (1994) ASSOCIATION OF THE INTERLEUKIN ONE RECEPTOR ANTAGONIST GENE POLYMORPHISM WITH LICHEN-SCLEROSUS. J INVEST DERMATOL, 103(3), 408-408.
Blakemore AI, Tarlow JK, Cork MJ, Gordon C, Emery P & Duff GW (1994) Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus.. Arthritis Rheum, 37(9), 1380-1385.
Tarlow JK, Clay FE, Cork MJ, Blakemore AI, McDonagh AJ, Messenger AG & Duff GW (1994) Severity of alopecia areata is associated with a polymorphism in the interleukin-1 receptor antagonist gene.. J Invest Dermatol, 103(3), 387-390.
Lewis FM, Cork MJ, McDonagh AJ & Gawkrodger DJ (1994) An audit of the value of patch testing: the patient's perspective.. Contact Dermatitis, 30(4), 214-216.
Cork MJ, Tarlow JK, Blakemore AI, Mee JB, Crane AM, Stierle C, Bleehen SS & Duff GW (1993) Psoriasis and interleukin-1. A translation.. J R Coll Physicians Lond, 27(4), 366.
Cork MJ, Tarlow JK, Wilson AG, Blakemore AIF, Messer G, Kind P, Gordon C, Emery P, Bleehen SS & Duff GW (1993) Cytokine gene polymorphisms in inflammatory dermatoses. Journal of Dermatological Science, 6(1), 18-18.
Mee JB, Cork MJ, di Giovine FS, Duff GW & Bleehen SS (1993) Cytokine gene activation across the advancing edge of psoriatic plaques. Journal of Dermatological Science, 6(1), 2-2.
CORK MJ, MEE JB, TARLOW JK, BLAKEMORE AIF, DIGIOVINE F, BLEEHEN SS & DUFF GW (1993) INTERLEUKIN ONE RECEPTOR ANTAGONIST POLYMORPHISM - ALLELIC ASSOCIATION WITH INFLAMMATORY DERMATOSES. J INVEST DERMATOL, 100(4), 448-448.
CORK MJ, TARLOW JK, BLAKEMORE AIF, MCDONAGH AJG, MESSENGER AG, BLEEHEN SS & DUFF GW (1993) GENETICS OF INTERLEUKIN ONE RECEPTOR ANTAGONIST IN INFLAMMATORY SKIN DISEASES. J INVEST DERMATOL, 100(4), 522-522.
CORK MJ, TARLOW JK, BLAKEMORE AIF, MCDONAGH AJG, MESSENGER AG, BLEEHEN SS & DUFF GW (1993) GENETICS OF INTERLEUKIN ONE RECEPTOR ANTAGONIST IN INFLAMMATORY SKIN DISEASES. CLIN RES, 41(2), A179-A179.
Stainforth J, MacDonald-Hull S, Papworth-smith J, Eady E, Cunliffe W, Norris J, Simpson N & Cork M (1993) A single-blind comparison of topical erythromycin/zinc lotion and oral minocycline in the treatment of acne vulgaris. Journal of Dermatological Treatment, 4(3), 119-122.
Lewis FM, Cork MJ, McDonagh AJ & Gawkrodger DJ (1993) Allergic contact dermatitis from resin-reinforced plaster.. Contact Dermatitis, 28(1), 40-41.
Barradell R, Addo A, McDonagh AJ, Cork MJ & Wales JK (1993) Phytophotodermatitis mimicking child abuse.. Eur J Pediatr, 152(4), 291-292.
McDonagh AJ, Wright AL, Cork MJ & Gawkrodger DJ (1992) Nickel sensitivity: the influence of ear piercing and atopy.. Br J Dermatol, 126(1), 16-18.
MCDONAGH AJG, CORK MJ & HARRINGTON CI (1991) PYODERMA-GANGRENOSUM. BRIT MED J, 303(6807), 925-925.
Gawkrodger DJ, Cork MJ & Bleehen SS (1991) Occupational vitiligo and contact sensitivity to para-tertiary butyl catechol.. Contact Dermatitis, 25(3), 200-201.
Cork MJ, Cooke NJ & Mellor E (1990) Pruritus ani, piperazine, and thrombocytopenia.. BMJ, 301(6765), 1398-1398.
Cork MJ, Riches AC & Wright EG (1986) A stimulator of murine haemopoietic stem cell proliferation produced by human fetal liver cells. British Journal of Haematology, 63(4), 775-783.
Cork MJ, Wright EG & Riches AC (1982) Regulation of murine granulocyte-macrophage progenitor cell and haemopoietic stem cell proliferation by factors produced in human fetal liver. Leukemia Research, 6(4), 553-565.
Thomas DB, Cork MJ & Riches AC (1981) The regulation of the haematopoietic stem cell compartment in foetal liver.. Progress in clinical and biological research, 59 B, 277-285.
Cork M, Anderson I, Thomas DB & Riches A (1981) Regulation of the growth fraction of CFU-S by an inhibitor produced by bone marrow. Leukemia Research, 5(1), 101-105.
Riches AC, Cork MJ & Thomas DB (1981) The control of haematopoietic stem cell proliferation by humoral factors.. Progress in clinical and biological research, 59 B, 269-276.
Riches AC, Cork MJ & Thomas DB (1980) Changes in the growth fraction of haempoietic stem cells following treatment with normal rat bone marrow extract. Cell and Tissue Kinetics, 13(2), 211-212.
Paller A, Eichenfield L, Silverberg J, Cork M, Bangert C, Irvine A, Weidinger S, Barbarot S, Fan H, Alderfer J , Koppensteiner H et al () Integrated Safety Analysis of Abrocitinib in 635 Adolescent Patients With Moderate-To-Severe Atopic Dermatitis With Over 1000 Patient-Years of Exposure. SKIN The Journal of Cutaneous Medicine, 8(2), s379-s379.
Wollenberg A, Cork M, Hong C-H, Kurbasic A, Vacko E & Paller A () Progressive and Sustained Disease Control in Patients with Atopic Dermatitis (AD) Aged 12–17 Years Treated with Tralokinumab for 52 Weeks. SKIN The Journal of Cutaneous Medicine, 8(2), s377-s377.
Cork MJ, Lockshin B, Pinter A, Chen Z, Shumel B & Prescilla R () Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator’s Global Assessment: A Post Hoc Analysis of a Phase 3 Trial. Acta Dermato-Venereologica, 104, adv13467-adv13467.
Cork M, Danby S, Rossi AB & Bansal A () Dupilumab Treatment in Pediatric Patients Aged 6–11 Years with Severe Atopic Dermatitis Whose Disease Is Not Adequately Controlled: A Review. Drug Design, Development and Therapy, Volume 18, 277-289.
Paller AS, Siegfried EC, Cork MJ, Arkwright PD, Eichenfield LF, Ramien M, Khokhar FA, Chen Z, Zhang A & Cyr SL () Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis. Pediatric Drugs.
Paller A, Cork M, Flohr C, Bangert C, Weidinger S, Nesnas J, Farooqui S, Biswas P, Watkins M & Koppensteiner H () Long-Term Efficacy of Abrocitinib in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE EXTEND. SKIN The Journal of Cutaneous Medicine, 8(1), s329-s329.
Paller A, Cork M, Hong C-H, Soong W, Schneider S, Lo H, Pedersen LRM, Vacko E & Wollenberg A () Laboratory Parameters in Adolescent Patients Aged 12–17 with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52: Results from the Phase 3 ECZTRA 6 Trial. SKIN The Journal of Cutaneous Medicine, 8(1), s323-s323.
Andrew PV, Pinnock A, Poyner A, Brown K, Chittock J, Kay LJ, Cork MJ & Danby SG () Maintenance of an Acidic Skin Surface with a Novel Zinc Lactobionate Emollient Preparation Improves Skin Barrier Function in Patients with Atopic Dermatitis. Dermatology and Therapy.
Williams SF, Wan H, Chittock J, Brown K, Wigley A, Cork MJ & Danby SG () Characterisation of skin barrier defects in atopic dermatitis patients using Infrared Spectroscopy. Clinical and Experimental Dermatology.
Simpson EL, Blauvelt A, Silverberg JI, Cork MJ, Katoh N, Mark T, Schneider SKR & Wollenberg A () Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1. American Journal of Clinical Dermatology.
Wollenberg A, Cork M, Flohr C, Bewley A, Blauvelt A, Hong C-H, Imafuku S, Schuttelaar MLA, Simpson E, Soong W , Amoudruz P et al () Safety of tralokinumab in pediatric patients aged 12-17 years with moderate to severe atopic dermatitis: results from the phase 3 ECZTRA 6 trial. SKIN The Journal of Cutaneous Medicine, 7(2), s140-s140.
Paller A, Silverberg J, Hong HCH, Cork M, Puig L, Arlert P, Kurbasic A, Soldbro L & Simpson E () The impact of tralokinumab on quality of life and school in patients aged 12-17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial. SKIN The Journal of Cutaneous Medicine, 7(2), s139-s139.
Paller AS, Silverberg JI, Cork MJ, Guttman-Yassky E, Lockshin B, Irvine AD, Kim MB, Kabashima K, Chen Z, Lu Y , Bansal A et al () Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis. JAMA Dermatology.
Paller AS, Silverberg JI, Hong C-H, Cork M, Puig L, Arlert P, Kurbasic A, Soldbro L & Simpson EL () The impact of tralokinumab on quality of life and school in patients aged 12–17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial. SKIN The Journal of Cutaneous Medicine, 6(6), s77-s77.
Kelleher MM, Phillips R, Brown SJ, Cro S, Cornelius V, Carlsen KCL, Skjerven HO, Rehbinder EM, Lowe AJ, Dissanayake E , Shimojo N et al () Skin care interventions in infants for preventing eczema and food allergy. Cochrane Database of Systematic Reviews, 2022(11).
McPherson T, Cork MJ, Goodhead C, Michaelis LJ, Flohr C, Petrovic M, Hennessy L, Rajkovic I & Hudson R () A real‐world retrospective observational study exploring NHS resource use in England for the management of moderate‐to‐severe atopic dermatitis in secondary care for children and adolescents. Pediatric Dermatology.
Paller AS, Beck LA, Blauvelt A, Siegfried EC, Cork MJ, Wollenberg A, Chen Z, Khokhar FA, Vakil J, Zhang A , Bansal A et al () Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis—A pooled analysis of trial data. Pediatric Dermatology.
Kelleher MM, Cro S, Van Vogt E, Cornelius V, Lodrup Carlsen KC, Skjerven HO, Rehbinder EM, Lowe A, Dissanayake E, Shimojo N , Yonezawa K et al () Skin care interventions in infants for preventing eczema and food allergy: a Cochrane systematic review and individual participant data meta‐analysis. Clinical & Experimental Allergy.
Kelleher MM, Cro S, Cornelius V, Lodrup Carlsen KC, Skjerven HO, Rehbinder EM, Lowe AJ, Dissanayake E, Shimojo N, Yonezawa K , Ohya Y et al () Skin care interventions in infants for preventing eczema and food allergy. Cochrane Database of Systematic Reviews.
Blaiss M, Cork M, Lio P, Kessel A, Takiya L, Werth J, O'Connell M, Zang C & Spergel J () Efficacy and Safety of Crisaborole in Patients With Mild-to-Moderate Atopic Dermatitis With and Without Food Allergies. SKIN The Journal of Cutaneous Medicine, 5(1), s12-s12.
Silverberg J, Barbarot S, Gooderham M, Simon J, Simpson E, Kurbasic A, Olsen C & Cork M () Specifically Targeting Interleukin-13 with Tralokinumab Improved Sleep in Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials in Patients with Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine, 5(1), s9-s9.
Spergel J, Blaiss M, Lio P, Kessel A, Takiya L, Werth J, O'Connell M, Zang C & Cork M () Efficacy and Safety of Crisaborole in Patients With Mild-to-Moderate Atopic Dermatitis With and Without Comorbid Allergic Rhinitis. SKIN The Journal of Cutaneous Medicine, 5(1), s13-s13.
Jabbar‐Lopez ZK, Ung CY, Alexander H, Gurung N, Chalmers J, Danby S, Cork MJ, Peacock JL & Flohr C () The effect of water hardness on atopic eczema and skin barrier function: A systematic review and meta‐analysis. Clinical & Experimental Allergy.
Silverberg JI, Cork M, Wollenberg A, Katoh N, Steffensen LA, Kurbasic A, Olsen CK, Kuznetsova A, Østerdal ML, Vilsbøll AW & Deleuran M () Early Changes in Patient-Relevant Endpoints in Three Tralokinumab Pivotal Phase 3 Trials (ECZTRA 1−3) in Adult Patients with Moderate-to-Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine, 4(6), s98-s98.
Cork M, Thaçi D, Eichenfield L, Arkwright P, Chen Z, Kamal M, O'Malley J & Bansal A () Dupilumab Provides Acceptable Long-Term Safety and Efficacy in Children Aged ≥ 6 to < 12 Years with Uncontrolled, Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine, 4(6), s104-s104.
Thyssen JP, Vestergaard C, Deleuran M, Bruin‐Weller MS, Bieber T, Taieb A, Seneschal J, Cork MJ, Paul C, Flohr C , Weidinger S et al () European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. Journal of the European Academy of Dermatology and Venereology.
Kelleher MM, Cro S, Cornelius V, Axon E, Lodrup Carlsen KC, Skjerven HO, Rehbinder EM, Lowe A, Dissanayake E, Shimojo N , Yonezawa K et al () Skincare interventions in infants for preventing eczema and food allergy. Cochrane Database of Systematic Reviews.
Cooke A, Victor S, Cork M & Lavender T () Topical oils for the prevention or treatment of dry skin in term infants. Cochrane Database of Systematic Reviews.
Cooke A, Victor S, Cork M & Lavender T () Topical oils for the prevention or treatment of dry skin in term infants. Cochrane Database of Systematic Reviews.
Cork MJ, Danby SG & Ogg GS () Atopic dermatitis epidemiology and unmet need in the United Kingdom. Journal of Dermatological Treatment. View this article in WRRO
Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Hultsch T, Davis JD, Zhang Y, Zhu X, Chen Z, Li M , Ardeleanu M et al () Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis : results from a phase IIa open‐label trial and subsequent phase III open‐label extension. British Journal of Dermatology. View this article in WRRO
Danby SG, Andrew PV, Brown K, Chittock J, Kay LJ & Cork MJ () Response to: Letter to the Editor Regarding “An Investigation of the Skin Barrier Restoring Effects of a Cream and Lotion Containing Ceramides in a Multi-Vesicular Emulsion in People with Dry, Eczema-Prone, Skin: The RESTORE Study Phase 1”. Dermatology and Therapy.
Jabbar‐Lopez ZK, Ezzamouri B, Briley A, Greenblatt D, Gurung N, Chalmers JR, Thomas KS, Frost T, Kezic S, Common JEA , Danby S et al () Randomized controlled pilot trial with ion‐exchange water softeners to prevent eczema (SOFTER trial). Clinical & Experimental Allergy.

Chapters

Danby SG & Cork MJ (2018) pH in Atopic Dermatitis, pH of the Skin: Issues and Challenges (pp. 95-107). S. Karger AG
Danby S, Bedwell C & Cork MJ (2014) Neonatal Skin Care and Toxicology In Eichenfield LF, Frieden IJ, Zaenglein A & Mathes E (Ed.), Neonatal and Infant Dermatology (pp. 46-56). Saunders
Cork MJ & Danby SG (2012) Current and Future Trends: Skin Diseases and Treatment In Benson HAE & Watkinson AC (Ed.), Topical and Transdermal Drug Delivery Wiley
Cork MJ & Danby S (2011) The Skin Barrier in Atopic Dermatitis. In Irvine A, Hoeger P & Yan A (Ed.), Textbook of Pediatric Dermatology, UK: Blackwell Publishing Ltd..
Cork MJ, Moustafa M, Danby S, Vasilopoulos Y, Tazi-Ahnini R, Ward SJ, Hadgraft J, Lane ME, Guy R & MacGowan A (2009) Skin Barrier Dysfunction in Atopic Dermatitis, Basic and Clinical Dermatology (pp. 211-240). Informa Healthcare
Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane M, Moustafa M, Guy R, MacGowan A, Tazi-Ahnini R & Ward SJ (2009) Epidermal Barrier Dysfunction in Atopic Dermatitis In Rawlings L (Ed.), Skin Moisturization USA: Informa Healthcare USA Inc..

Conference proceedings papers

Cork MJ, Leung DYM, Ong P, Danby SG, Ramirez-Gama M, Garcia S, Taylor P, Zahn J, Praestgaard A, Bologna G & Zhang A (2023) 55 Dupilumab treatment normalizes skin barrier function and improves patient-reported outcomes in patients aged 6 to 11 years with moderate-to-severe atopic dermatitis. Journal of Investigative Dermatology, Vol. 143(11) (pp S342-S342)
Pinter A, Cork MJ, Siegfried EC, Arkwright PD, Wollenberg A, Eichenfield LF, Ramien M, Khokhar FA, Chen Z, Zhang A & Cyr SL (2023) Dupilumab Treatment is Not AssociatedWith an Increased Overall Risk of Infections in Patients Aged 6 Months to 5 yearsWithModerate-to-Severe Atopic Dermatitis. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 21 (pp 100-101)
Paller A, Siegfried E, Sidbury R, Lockshin B, Cork M, Pinter A, Xiao J, Stanton S, Khokhar F, Bansal A & Prescilla R (2023) Treatment-Emergent Adverse Events in Patients Aged 6 Months to 5 Years With Moderate-to- Severe Atopic Dermatitis Treated With Dupilumab in an Open-Label Extension Clinical Trial. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 89(3) (pp AB100-AB100)
Wollenberg A, Cork MJ, Flohr C, Bewley A, Blauvelt A, Hong-H C-H, Imafuku S, Schuttelaar M-LA, Simpson E, Soong W , Amoudruz P et al (2023) SAFETY OF TRALOKINUMAB IN PAEDIATRIC PATIENTS AGED 12-17 WITH MODERATE-TO-SEVERE AROPIC DERMATITIS: RESULTS FROM THE PHASE 3 ECZTRA 6 TRIAL. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 21 (pp 58-58)
Weidinger S, Cork M, Reich A, Bieber T, Gilbert S, Quaratino S, Wilson R & Porter-Brown B (2023) Safety of Amlitelimab in a Phase 2a Clinical Trial of Patients With Moderate-to-Severe Atopic Dermatitis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 89(3) (pp AB221-AB221)
Wollenberg A, Cork MJ, Hong HC-H, Taveira CM, Kurbasic A, Vacko E & Paller AS (2023) PROGRESSIVE AND SUSTAINED DISEASE CONTROL IN PATIENTS WITH ATOPIC DERMATITIS (AD) AGED 12-17 YEARS TREATED WITH TRALOKINUMAB FOR 52 WEEKS. ACTA DERMATO-VENEREOLOGICA, Vol. 103 (pp 30-30)
Simpson E, Paller A, Wollenberg A, Bewley A, Cork M, Hong C-H, Soong W, Almgren P, Carlsson A & Blauvelt A (2023) Long-term safety and efficacy of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: an interim analysis of ECZTEND. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 89(3) (pp AB190-AB190)
Wollenberg A, Paller AS, Bewley A, Cork M, Hong C-H, Soong W, Oland CB, Taveira CM, Gjerum L & Blauvelt A (2023) LONG-TERM EFFICACY OF TRALOKINUMAB IN ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS. ACTA DERMATO-VENEREOLOGICA, Vol. 103 (pp 54-54)
Paller AS, Ramien M, Cork MJ, Simpson EL, Lee LW, Eichenfield LF, Coleman A, Gherardi G, Tian T, Zhang A & Cyr SL (2023) LONG-TERM DUPILUMAB TREATMENT IS NOT ASSOCIATED WITH AN INCREASED OVERALL RISK OF INFECTIONS IN PATIENTS AGED 6 MONTHS TO 5 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS IN AN OPENLABEL EXTENSION STUDY. ACTA DERMATO-VENEREOLOGICA, Vol. 103 (pp 54-54)
Siegfried E, Cork MJ, Lockshin B, Boguniewicz M, Uppal S, Vass M, Khokhar FA, Bansal A, Sierka D & Cyr S (2023) Long Term Hematologic Laboratory Safety of Dupilumab in Patients Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 89(3) (pp AB62-AB62)
Paller A, Eichenfield LF, Cork MJ, Bangert C, Irvine AD, Weidinger S, Johnson S, Lazariciu I & Koppensteiner H (2023) Integrated Analysis of Abrocitinib for the Treatment of Adolescents with Moderate-to-Severe Atopic Dermatitis From the Phase 3 Clinical Trial Program. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 21 (pp 77-77)
Cork MJ, Paller AS, Siegfried EC, Xiao J, Prescilla R, Dubost-Brama A & Bansal A (2023) EFFICACY AND SAFETY OF DUPILUMAB TREATMENT UP TO 1 YEAR IN INFANTS AND PRESCHOOL CHILDREN WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS. ACTA DERMATO-VENEREOLOGICA, Vol. 103 (pp 53-53)
Cork MJ, Leung DYM, Ong P, Danby SG, Ramirez-Gama M, Garcia S, Taylor P, Zahn J, Praestgaard A, Bologna G & Zhang A (2023) Dupilumab treatment normalizes skin barrier function and improves patient-reported outcomes in patients aged 6 to 11 years with moderate-to-severe atopic dermatitis. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 143(11) (pp S342-S342)
Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Praestgaard A, Prescilla R, Wang Z & Marco AR (2023) Dupilumab Treatment Improves Sleep Quality in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis and Their Caregivers. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 89(3) (pp AB40-AB40)
Cork MJ, Beck LA, Deleuran M, Hong HC-H, Adam DN, Hussain I, Zhang H, Shabbir A, Rodriguez Marco A & Levit NA (2022) Sustained long-term dupilumab efficacy in adult patients with moderate-to-severe atopic dermatitis transitioning from weekly dosing to every other week: Results from an open-label extension trial. CLINICAL AND EXPERIMENTAL ALLERGY, Vol. 52(8) (pp 1014-1014)
Cork MJ, Wollenberg A, Siegfried E, Chen Z, Levit NA & Rodriguez Marco A (2022) Dupilumab treatment is associated with reductions in serum immunoglobulin E and thymus and activation-regulated chemokine levels in children aged 6 to 11 years with severe atopic dermatitis. CLINICAL AND EXPERIMENTAL ALLERGY, Vol. 52(8) (pp 1059-1059)
Cork MJ, Papp KA, Deleuran M, Pink AE, Reich K, Biswas P, Chan G, Feeney C, Chiu WS & Randall RM (2022) Long-term efficacy of abrocitinib after initial successful treatment in patients with atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187 (pp 72-72)
Flohr C, Jones A, Rosala-Hallas A, Beattie P, Baron S, Browne F, Brown S, Gach J, Hearn R, Esdaile B , Cork M et al (2022) A randomized controlled trial assessing the effectiveness and safety of ciclosporin vs. methotrexate in the treatment of severe atopic eczema in children and young people: the TREatment of severe Atopic eczema Trial (TREAT). BRITISH JOURNAL OF DERMATOLOGY, Vol. 187 (pp 13-14)
Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Soong W, Gonzalez ME, Schneider LC, Sidbury R , Lockshin B et al (2022) Efficacy and safety of dupilumab in children aged >= 6 months to < 6 years with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 186(4) (pp E173-E173)
Paller AS, Cork MJ, Siegfried EC, Guttman-Yassky E, Simpson EL, Soong W, Xiao J, Wang Z, Chuang C-C, O'Malley JT & Bansal A (2022) Efficacy and safety of dupilumab in children aged 6-11 years with inadequately controlled severe atopic dermatitis: results from an open-label extension trial up to 1 year. BRITISH JOURNAL OF DERMATOLOGY, Vol. 186(4) (pp E159-E160)
Paller A, Blauvelt A, Soong W, Imafuku S, Hong C-H, Schuttelaar MLA, Amoudruz P, Kurbasic A, Soldbro L, Lophaven K , Cork M et al (2022) Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase III ECZTRA 6 trial. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187(3) (pp E90-E91)
Simpson E, Blauvelt A, Silverberg JI, Cork M, Katoh N, Mark T, Schneider S & Wollenberg A (2022) Clinically meaningful responses achieved with tralokinumab in adults with moderate-to-severe atopic dermatitis who did not meet IGA 0/1 at initial 16-week treatment. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 142(8) (pp B17-B17)
Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Zhang H, Wang Z & Marco AR (2022) Dupilumab treatment improved sleep quality in moderate-to-severe atopic dermatitis in children aged 6 months-5 years and their caregivers. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187(3) (pp E112-E113)
Weidinger S, Cork M, Reich A, Beiber T, Gilbert S, Brennan N, Wilson R, Quaratino S & Porter-Brown B (2022) A phase IIa study of amlitelimab, a novel nondepleting anti-OX40Ligand mAb in patients with moderate to severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187(3) (pp E96-E96)
Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Zhang H, Wang Z & Rodriguez Marco A (2022) Dupilumab treatment improves health-related quality of life in children aged 6 months-5 years with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187(3) (pp E104-E105)
Paller AS, Cork MJ, Siegfried EC, Simpson EL, Wollenberg A, Gonzalez ME, Sun Y, O'Malley JT & Bansal A (2022) Efficacy and safety of dupilumab in children aged >= 6 months to < 6 years with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187 (pp 12-12)
Cork M, Beck L, Bissonnette R, Wollenberg A, Simpson E, Praestgaard A, Aamodt K & Rossi A (2022) Dupilumab provides long-term efficacy over 2.5 years in adults with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187 (pp 69-69)
Cork MJ, Yosipovitch G, Silverberg JI, Praestgaard A, Zhang H, Wang Z & Rossi AB (2022) Dupilumab provides long-term improvement in pruritus in children with severe atopic dermatitis and adolescents and adults with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187 (pp 79-79)
Paller A, Blauvelt A, Soong W, Imafuku S, Hong C, Schuttelaar MLA, Amoudruz P, Kurbasic A, Soldbro L, Lophaven K , Schneider S et al (2022) Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase III ECZTRA 6 trial. BRITISH JOURNAL OF DERMATOLOGY, Vol. 186(4) (pp E145-E146)
Danby SG, Andrew PV, Taylor RN, Kay LJ, Chittock J, Pinnock A, Ulhaq I, Fasth A, Carlander K, Holm T , Cork MJ et al (2022) EFFECTS OF EMOLLIENT CREAMS ON THE SKIN BARRIER OF PATIENTS WITH ATOPIC DERMATITIS. ACTA DERMATO-VENEREOLOGICA, Vol. 102 (pp 35-36)
Cork MJ, Lockshin B, Blauvelt A, Chen Z, Khokhar FA, Bansal A & Prescilla R (2021) 161 52-Week Laboratory Safety Findings From an Open-Label Extension Study of Dupilumab in Adolescent Patients With Atopic Dermatitis (LIBERTY AD PED-OLE) (pp a68.2-a6a69)
Cork MJ, Wollenberg A, Siegfried EC, Arkwright PD, Chen Z, Levit NA, Marco AR & Radwan A (2021) Dupilumab is effective in children aged 6-11 years with severe atopic Dermatitis (AD) regardless of baseline serum total immunoglobulin E levels. CLINICAL AND EXPERIMENTAL ALLERGY, Vol. 51(12) (pp 1659-1659)
Paller A, Wollenberg A, Cork M, Siegfried E, Chen Z, Vakil J, Levit N, Marco AR & Radwan A (2021) Dupilumab treatment leads to mild transient increases in eosinophil levels without clinical relevance in children aged 6-11 years with severe atopic dermatitis. CLINICAL AND EXPERIMENTAL ALLERGY, Vol. 51(12) (pp 1687-1688)
Cork MJ, Lockshin B, Blauvelt A, Chen Z, Vakil J & Khokhar FA (2021) Fifty-two-week laboratory safety findings from an open-label extension study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE). BRITISH JOURNAL OF DERMATOLOGY, Vol. 185(3) (pp E121-E121)
Cork MJ, Thaci D, Eichenfield L, Arkwright PD, Chen Z, O'Malley JT & Bansal A (2021) Long-term efficacy and safety data for dupilumab in a phase III open-label extension trial (LIBERTY AD PED-OLE) in patients aged >= 6 to < 12 years with uncontrolled moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 185(3) (pp E115-E116)
Cork MJ, Lockshin B, Blauvelt A, Chen Z, Khokhar FA, Bansal A & Prescilla R (2021) 52-week laboratory safety findings from an open-label extension (OLE) study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE). JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 85(3) (pp AB120-AB120)
Cork MJ, Thaci D, Eichenfield L, Arkwright PD, Chen Z, Delevry D, O'Malley JT & Bansal A (2021) Long-term efficacy and safety data for dupilumab in a phase 3, open-label extension trial (LIBERTY AD PED-OLE) in patients aged >= 6 to < 12 years with uncontrolled, moderate-to-severe atopic dermatitis (AD). JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 85(3) (pp AB120-AB120)
Paller AS, Cork MJ, Marcoux D, Wollenberg A, Prescilla R, Chen Z, Rossi AB & Shumel B (2021) Dupilumab improves Eczema Area and Severity Index regional scores across all anatomical regions in children aged 6-11 years with severe atopic dermatitis (AD). JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 85(3) (pp AB136-AB136)
Paller A, Cork MJ, Marcoux D, Zhang H, Chuang C, Zhang A & Chao J (2021) Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs and symptoms and quality of life (QoL) in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 141(5) (pp S84-S84)
Wollenberg A, Thaci D, Cork MJ, Arkwright PD, Gooderham M, Sun X, O'Malley JT, Khokhar FA, Bansal A & Shumel B (2021) LABORATORY SAFETY OF DUPILUMAB IN PEDIATRIC PATIENTS AGED >= 6-< 12 YEARS WITH SEVERE ATOPIC DERMATITIS: RESULTS FROM A PHASE 3 TRIAL (LIBERTY AD PEDS). ACTA DERMATO-VENEREOLOGICA, Vol. 101 (pp 59-59)
Cork MJ, Thaci D, Eichenfield LF, Arkwright PD, Chen Z, Prescilla R, Delevry D, O'Malley JT & Bansal A (2021) LONG-TERM EFFICACY AND SAFETY OF DUPILUMAB IN A PHASE 3 OPEN-LABEL EXTENSION TRIAL (LIBERTY AD PED-OLE) IN PATIENTS AGED >= 6 TO < 12 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS. ACTA DERMATO-VENEREOLOGICA, Vol. 101 (pp 60-60)
Cork MJ, Thaci D, Eichenfield L, Arkwright PD, Bastian M, Chen Z, Delevry D, O'Malley JT & Bansal A (2021) Long-term efficacy and safety data for dupilumab in a phase 3, Open-Label Extension Trial (LIBERTY AD PED-OLE) in patients aged >= 6 to < 12 years with moderate-to-severe atopic dermatitis (AD). JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 19 (pp 14-14)
Lio P, Cork MJ, Blaiss MS, Kessel A, Cantrell WC, Werth JL, O'Connell M, Zang C & Takiya L (2021) Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis with and without comorbid allergies or asthma. BRITISH JOURNAL OF DERMATOLOGY, Vol. 185(3) (pp E110-E110)
Bewley A, Thyssen JP, Chiu WS, Rojo R, Biswas P, Feeney C, DiBonaventura M, Misery L, Stander S & Cork M (2021) Impact of abrocitinib on itch, sleep, skin pain and psychological stress in patients with moderate-to-severe atopic dermatitis: pooled analysis from JADE monotherapy trials. BRITISH JOURNAL OF DERMATOLOGY, Vol. 185(3) (pp E72-E73)
Paller AS, Weidinger S, Cork MJ, Marcoux D, Katoh N, Zhang H, Rossi AB, Shumel B, Zhang A, Prescilla R & Chao J (2021) Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs, symptoms, and quality of life in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 85(3) (pp AB141-AB141)
Lio PA, Spergel JM, Cork MJ, Blaiss MS, Kessel A, Cantrell WC, Werth JL, O'Connell MA, Zang C & Takiya L (2021) Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis with and without comorbid allergies or asthma. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 85(3) (pp AB97-AB97)
Simon JC, Barbarot S, Gooderham M, Simpson E, Kurbasic A, Olsen CK, Cork MJ & Silverberg JI (2021) The targeted Action on Interleukin-13 with Tralokinumab improved the Sleep in two randomized, double-blind, placebo-controlled Phase III Studies in Patients with atopic Dermatitis. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 19 (pp 56-56)
Silverberg JI, Barbarot S, Gooderham M, Simon JC, Simpson E, Kurbasic A, Olsen CK & Cork MJ (2021) Specifically targeting interleukin-13 with tralokinumab improved sleep in two phase III, randomized, double-blind, placebo-controlled trials in patients with atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 184(3) (pp E64-E65)
Silverberg JI, Cork M, Wollenberg A, Katoh N, Steffensen LA, Kurbasic A, Olsen CK, Kuznetsova A, Osterdal ML, Vilsboll AW , Deleuran M et al (2021) Early changes in patient-relevant endpoints in three tralokinumab pivotal phase III trials (ECZTRA 1-3) in adult patients with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 184(3) (pp E64-E64)
Danby SG, Andrew PV, Pinnock A, Kay L, Chittock J & Cork MJ (2021) LOWERING SKIN SURFACE PH WITH A TOPICAL ZINC LACTOBIONATE PREPARATION CONTAINING PHYSIOLOGIC LIPIDS IMPROVES SKIN BARRIER STRUCTURE AND FUNCTION IN ADULTS WITH ATOPIC DERMATITIS. ACTA DERMATO-VENEREOLOGICA, Vol. 101 (pp 51-51)
Wollenberg A, Thaci D, Cork MJ, Arkwright PD, Gooderham M, Sun X, Vakil J & Khokhar FA (2021) Laboratory safety of dupilumab in paediatric patients aged >= 6 to < 12 years with severe atopic dermatitis: results from a phase III trial (LIBERTY AD PEDS). BRITISH JOURNAL OF DERMATOLOGY, Vol. 185(3) (pp E122-E123)
Chalmers JR, Haines RH, Bradshaw LE, Montgomery AA, Thomas KS, Brown SJ, Ridd M, Lawton S, Simpson EL, Cork MJ , Sach TH et al (2021) A RANDOMISED CONTROLLED TRIAL OF DAILY EMOLLIENT DURING INFANCY FOR PREVENTING ECZEMA - RESULTS OF THE BEEP TRIAL. ACTA DERMATO-VENEREOLOGICA, Vol. 101 (pp 7-8)
Danby SG, Andrew P, Kay L, Pinnock A, Chittock J, Brown K & Cork MJ (2020) An investigation of the skin barrier restoring effects of a cream containing ceramides in a multivesicular emulsion in people with dry, eczema-prone, skin: The RESTORE study phase 2. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 83(6) (pp AB71-AB71)
Cork MJ, Lockshin B, Morren M-A, Etoh T, Chen Z, Rossi AB, Lu Y, Bansal A & Shabbir A (2020) Dupilumab improves signs and symptoms in adult and adolescent patients with erythrodermic atopic dermatitis: A pooled subgroup analysis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 83(6) (pp AB39-AB39)
Flohr C, Beattie P, Cork M, Brown S, Burton T, Gholam K, Griffiths C, Ingram J, Irvine A, Langan S , Manca A et al (2020) The use of systemic immunomodulatory agents in the treatment of children and adolescents with atopic eczema: lessons from the UK-Irish Atopic Eczema Systemic Therapy (A-STAR) Register. BRITISH JOURNAL OF DERMATOLOGY, Vol. 183 (pp 147-148)
Shabbir A, Paller AS, Lockshin B, Cork MJ, Morren M, Kataoka Y, Chen Z, Rossi AB & Lu Y (2020) Dupilumab monotherapy improves signs, symptoms and quality of life in adult and adolescent patients with erythrodermic atopic dermatitis. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 140(7) (pp S60-S60)
Simpson EL, Sinclair R, Forman S, Wollenberg A, Asch R, Cork M, Bieber T, Thyssen JP, Yosipovitch G, Magnolo N , Maari C et al (2020) Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: results from the phase III, JADE MONO-1 study. BRITISH JOURNAL OF DERMATOLOGY, Vol. 183(4) (pp E105-E106)
McPherson T, Cork M, Michaelis L, Flohr C, Davis L, Petrovic M, Hennessy L, Rajkovic I & Hudson R (2020) A real-world observational study to describe National Health Service resource use for the management of moderate-to-severe atopic dermatitis in secondary care for children and adolescents aged 6-17 years. BRITISH JOURNAL OF DERMATOLOGY, Vol. 183 (pp 147-147)
Cork MJ, Eichenfield LF, Blauvelt A, Rosmarin D, Hussain I, Davis JD, Li M, Zhang Q, Gadkari A, Eckert L , Kamal MA et al (2019) 605 Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis. Journal of Investigative Dermatology, Vol. 139(5) (pp s104-s104), 8 May 2019 - 11 May 2019. View this article in WRRO
Cork MJ, Eichenfield LF, Blauvelt A, Rosmarin D, Hussain I, Davis JD, Li M, Zhang Q, Gadkari A, Eckert L , Kamal MA et al (2019) Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 139(5) (pp S104-S104)
de Bruin-Weller M, Eckert L, Simpson EL, Cork MJ, Ardeleanu M, Chen Z, Shumel B, Rossi AB, Graham NMH, Pirozzi G & Gadkari A (2019) Clinically meaningful responses in moderate-to-severe atopic dermatitis patients treated with Dupilumab. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 17 (pp 116-116)
Chittock J, Brown K, Cork MJ & Danby SG (2018) Quantification of natural moisturizing factors at the skin surface using a portable infrared spectrometer device: a pilot, calibration model. BRITISH JOURNAL OF DERMATOLOGY, Vol. 179(1) (pp E35-E36) View this article in WRRO
Cork MJ, Thaci D, Davis JD, Zhang Q, Akinlade B, Graham NMH, Pirozzi G & Bansal A (2017) An open-label phase IIa trial assessing the pharmacokinetics, safety and efficacy of dupilumab in a paediatric population with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 177 (pp 155-155)
Cork MJ, Thaci D, Davis JD, Zhang Q, Akinlade B, Graham NMH, Pirozzi G & Bansal A (2017) An open-label phase IIa trial assessing the pharmacokinetics, safety and efficacy of dupilumab in a paediatric population with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 177 (pp 67-68)
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour J-P , Kingo K et al (2017) Dupilumab in moderate-to-severe atopic dermatitis: results from two randomized phase 3 trials (SOLO 1 & 2). JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 15 (pp 79-79)
Byers RA, Maiti R, Danby SG, Pang EJ, Mitchell B, Carré MJ, Lewis R, Cork MJ & Matcher SJ (2017) Characterizing the microcirculation of atopic dermatitis using angiographic optical coherence tomography. Proceedings of SPIE, Vol. 10037 View this article in WRRO
Danby S, Wan H, Chittock J, Brown K, Wigley A & Cork M (2016) Characterisation of the skin barrier defect in atopic dermatitis using in vivo ATR-FTIR spectroscopy. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 136(9) (pp S182-S182)
Cooke A, Cork M, Victor S, Campbell M, Danby S, Chittock J & Lavender T (2015) A pilot, assessor-blinded, randomized controlled trial of topical oils for neonatal skin. BRITISH JOURNAL OF DERMATOLOGY, Vol. 173 (pp 153-153)
Danby S, Brown K, Higgs-Bayliss T, Chittock J & Cork M (2014) The effect of a complex emollient cream containing 5% urea, ceramide 3 and lactic acid, compared with a simple emollient, on the skin barrier in older people with dry skin. BRITISH JOURNAL OF DERMATOLOGY, Vol. 171 (pp 57-58)
Chalmers JR, Simpson EL, Chen YY, Cork MJ, Brown SJ, Thomas KS, Williams HC & Grp BEEPS (2014) Feasibility study of Barrier Enhancement For Eczema Prevention (BEEP). BRITISH JOURNAL OF DERMATOLOGY, Vol. 170(6) (pp E8-E9)
Higgs-Bayliss T, Brown K, Chittock J, Cork MJ & Danby SG (2014) Noninvasive assessment of the lipid structure and water holding properties of the stratum corneum in vivo by ATR-FTIR using a fibre optic probe in patients with atopic dermatitis and healthy controls. BRITISH JOURNAL OF DERMATOLOGY, Vol. 170(6) (pp E29-E29)
Chalmers JR, Thomas KS, Montgomery A, Sach T, Boyle RJ, Ridd MJ, Simpson EL, Cork MJ, Brown SJ, Lawton S , Thornton J et al (2014) A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial). BRITISH JOURNAL OF DERMATOLOGY, Vol. 170(6) (pp E32-E32)
Shareef MS, Albenali L, Cork MJ & Clark SM (2013) A difficult case of atopic eczema: useful learning points. BRITISH JOURNAL OF DERMATOLOGY, Vol. 169 (pp 120-120)
Danby S, Chittock J, Martin KM, Cork MJ & Tierney NK (2013) Chymotrypsin-like protease activity in the stratum corneum is increased in atopic dermatitis and upon washing with soap. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 68(4) (pp AB172-AB172)
Cork MJ (2012) Skin barrier breakdown in atopic dermatitis: the effect of topical products. INTERNATIONAL JOURNAL OF COSMETIC SCIENCE, Vol. 34(4) (pp 363-364)
Albenali L, Danby S, Moustafa M, Chittock J, Kennedy K, Shackley F & Cork MJ (2012) Vitamin D supplementation improves atopic dermatitis and atopic dermatitis complicated by eczema herpeticum. BRITISH JOURNAL OF DERMATOLOGY, Vol. 167 (pp 127-127)
Danby S, Al Enezi T, Chittock J, Kennedy K, Sultan A & Cork M (2011) A randomized comparison of aqueous cream and Oilatum (R) Junior bath additive on skin barrier function in atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 165 (pp 115-115)
Danby S, Al Enezi T, Chittock J, Kennedy K, Sultan A & Cork M (2011) A randomized comparison of aqueous cream and Oilatum (R) Junior bath additive on skin barrier function in atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 165 (pp 44-45)
Moustafa M, Holden C, Athavale P, Cork M, Messenger A & Gawkrodger DJ (2009) Patch testing is a useful investigation in children with eczema. BRITISH JOURNAL OF DERMATOLOGY, Vol. 161 (pp 125-125)
Al Enezi T, Sultan A, Chittock J, Moustafa M, Danby S & Cork MJ (2009) Breakdown of the skin barrier induced by aqueous cream: implications for the management of atopic eczema. BRITISH JOURNAL OF DERMATOLOGY, Vol. 161 (pp 115-116)
Danby S, Moustafa M, MacGowan AL, Ward SJ & Cork MJ (2009) Skin protease inhibitors: a new treatment for atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 161 (pp 30-31)
Danby S, Moustafa M, MacGowan AL, Ward SJ & Cork MJ (2009) Skin protease inhibitors: A new treatment for atopic dermatitis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 60(3) (pp AB67-AB67)
Carr J, Akram M, Sultan A, Hunter L, Moustafa M, Messenger AG, Fenton P & Cork MJ (2008) Contamination of emollient creams and ointments with Staphylococcus aureus in children with atopic eczema. BRITISH JOURNAL OF DERMATOLOGY, Vol. 159 (pp 114-114)
Harcastle NJ, MacGowan AL, Henderson JK, Cork MJ & Ward SJ (2008) Vitamin A metabolic pathway inhibition: a new therapeutic approach to treating psoriasis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 159 (pp 118-118)
Cork MJ, Varghese J, Hadcraft J, Lane M, Ferguson A, Moustafa M, Guy RH & Ward S (2007) Differences in the effect of topical corticosteroids and calcineurin inhibitors on the skin barrier - Implications for therapy. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 127 (pp S45-S45)
Kemp EH, McDonagh AJG, Wengraf DA, Messenger AG, Gawkodger DJ, Cork MJ & Tazi-Ahnini R (2007) Severe alopecia areata is associated with a functional polymorphism in the PTPN22 gene. IMMUNOLOGY, Vol. 120 (pp 70-70)
Cork M, Robinson D, Vasilopoulos Y & Ferguson A (2007) The effects of topical corticosteroids and pimecrolimus skin barrier function, gene expression, and topical drug penetration in atopic eczema and unaffected controls. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 56(2) (pp AB69-AB69)
Simon M, Tazi-Ahnini R, Jonca N, Cork MJ & Serre G (2006) Reduced and abnormal proteolysis of corneodesmosomal proteins in psoriatic skin. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 126 (pp 116-116)
Lovewell TRJ, Cork MJ, Wengraf DA, Messenger AG, McDonagh AJG & Tazi-Ahnini R (2006) A study on the effect of genetic variants of the autoimmune regulator (AIRE) promoter, on AIRE activity and downstream Aire-regulated genes. BRITISH JOURNAL OF DERMATOLOGY, Vol. 155(1) (pp 250-250)
Vasilopoulos Y, Cork MJ, Sagoo GS, Ward SJ, Duff GW & Tazi-Ahnini R (2006) A synonymous single nucleotide polymorphism in human cystatin A, a candidate gene in the PSORS5 locus, confers susceptibility to psoriasis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 155(1) (pp 235-235)
Cork M, Robinson D, Vasilopoulos Y & Ferguson A (2006) Interaction of topical corticosteroids and pimecrolimus with the skin barrier: Implications for efficacy and safety of treatment for atopic dermatitis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 54(3) (pp AB3-AB3)
Cork MJ, Robinson D, Vasilopoulos Y, Ferguson A, Moustafa M, Tazi-Ahnini R & Ward SJ (2005) Skin barrier damage: Cause or consequence of atopic dermatitis?. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 125(3) (pp 605-605)
Cork MJ, Robinson DA, Vasilopoulos Y, Ferguson A, Moustafa M, Tazi-Ahnini R & Ward SJ (2005) Treatment of atopic dermatitis from a skin barrier perspective. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 125(3) (pp 611-611)
Cork M (2005) Skin barrier damage: Cause or consequence of atopic dermatitis?. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 52(3) (pp P9-P9)
Cork MJ, Timmins J, Holden C, Carr J, Berry V, Tazi-Ahnini R & Ward SJ (2004) An audit of adverse drug reactions to aqueous cream in children with atopic eczema. BRITISH JOURNAL OF DERMATOLOGY, Vol. 151 (pp 57-58)
Simon M, Tazi-Ahnini R, Cork MJ & Serre G (2003) Abnormal proteolysis of corneodesmosin in psoriatic skin. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 121(6) (pp 1568-1568)
Tazi-Ahnini R, Vasilopoulos Y, Henderson JK, Murphy R, Williams H, Ward SJ, Duff GW & Cork MJ (2003) Role of variants within genes regulating the skin barrier in the pathogenesis of atopic eczema. BRITISH JOURNAL OF DERMATOLOGY, Vol. 149 (pp 4-4)
Wengraf DA, McDonagh AJG, Cork MJ, Gawkrodger D, Messenger AG & Tazi-Ahnini R (2003) Genetic analysis of the autoimmune regulator (aire) gene: potential role of aire in susceptibility to alopecia universalis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 148(4) (pp 849-850)
McDonagh AJG, Messenger AG, Birch MP, Cork MJ & Tazi-Ahnini R (2003) Alopecia areata: age at onset, atopy & disease associations. BRITISH JOURNAL OF DERMATOLOGY, Vol. 148(4) (pp 866-867)
Price VH, Stenn KS, Duvic M, Goldsmith LA, Cork MJ, Happle R, Kalabokes V & Moshell AN (1999) Introduction. Journal of Investigative Dermatology Symposium Proceedings, Vol. 4(3) (pp 199-199)
CORK M (1996) The role of in atopic eczema: treatment strategies. Journal of the European Academy of Dermatology and Venereology, Vol. 7 (pp S31-S37)
Paller A, Blauvelt A, Soong W, Imafuku S, Hong C-H, Schuttelaar M, Amoudruz P, Kurbasic A, Soldbro L, Lophaven K , Cork M et al () Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial. SKIN The Journal of Cutaneous Medicine, Vol. 6(2) (pp s29-s29)

Reports

Danby SG, Ewence A, Rumsby P, Cork MJ, Williams HC, Rockett L & Davey HMSAUIII-PP (2011) A systematic review of skin irritation and tap water

Posters

Weidinger S, Cork M, Reich A, Bieber T, Gilbert S, Quaratino S, Wilson R & Porter-Brown B (2023) 41343 Safety of Amlitelimab in a Phase 2a Clinical Trial of Patients With Moderate-to-Severe Atopic Dermatitis.
Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Praestgaard A, Prescilla R, Wang Z & Rodriguez Marco A (2023) 41817 Dupilumab Treatment Improves Sleep Quality in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis and Their Caregivers.
Simpson E, Paller A, Wollenberg A, Bewley A, Cork M, Hong C-H, Soong W & Almgren P (2023) 43997 Long-term safety and efficacy of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: an interim analysis of ECZTEND.
Paller A, Siegfried E, Sidbury R, Cork M, Pinter A, Xiao J, Stanton S, Khokhar F, Bansal A & Prescilla R (2023) 42924 Treatment-Emergent Adverse Events in Patients Aged 6 Months to 5 Years With Moderate-to- Severe Atopic Dermatitis Treated With Dupilumab in an Open-Label Extension Clinical Trial.
Siegfried E, Cork MJ, Lockshin B, Boguniewicz M, Uppal S, Vass M, Khokhar FA, Bansal A, Sierka D & Cyr S (2023) 42008 Long Term Hematologic Laboratory Safety of Dupilumab in Patients Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis.
Katibi OS, Andrew P, Poyner A, Pinnock A, Brown K, Byers R, Cork M & Danby S (2023) P24 Emollient use and effects on cutaneous allergen reactions: a preliminary study.
Cork M, Bissonnette R, Ramirez-Gama M, Taylor P, Praestgaard A, Levit N, Rossi A & Zhang A (2023) P40 Dupilumab treatment restores skin barrier function in lesional and nonlesional skin of patients with atopic dermatitis and improves patient-reported outcomes.
Paller AS, Cork MJ, Wollenberg A, Siegfried EC, Gonzalez ME, Lockshin B, Khokhar FA, Chen Z, Gonzalez T, Simcox E & Prescilla R (2023) P73 Laboratory safety from a 16-week phase III study of dupilumab in patients aged 6 months–5 years with moderate-to-severe atopic dermatitis.
Paller AS, Cork MJ, Flohr C, Bangert C, Weidinger S, Nesnas J, Farooqui SA, Biswas P, Watkins M & Koppensteiner H (2023) P81 Long-term efficacy of abrocitinib in adolescents and adults with moderate-to-severe atopic dermatitis: a post hoc analysis of JADE EXTEND.
Siegfried EC, Cork MJ, Boguniewicz M, Deleuran M, Simpson EL, Chen Z, Clearfield D, Shah P & Marco AR (2023) 410 Dupilumab treatment reduces total IgE levels in patients 6 months and older with moderate-to-severe atopic dermatitis.
Paller AS, Eichenfield LF, Silverberg JI, Cork MJ, Bangert C, Irvine AD, Weidinger S, Barbarot S, Fan H, Alderfer J , Koppensteiner H et al (2023) 383 Integrated safety analysis of abrocitinib in 635 adolescent patients with moderate-to-severe atopic dermatitis with over 1000 patient-years of exposure.
Paller AS, Siegfried EC, Sidbury R, Lockshin B, Cork M, Pinter A, Xiao J, Khokhar FA, Bansal A & Prescilla R (2023) 437 Treatment-emergent adverse events in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis treated with dupilumab in an open-label extension clinical trial.
Siegfried E, Cork MJ, Lockshin B, Boguniewicz M, Uppal S, Khokhar FA, Bansal A, Sierka D & Cyr S (2023) 411 Long term laboratory safety of dupilumab in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis.
Weidinger S, Cork M, Reich A, Bieber T, Gilbert S, Quaratino S, Wilson R & Porter-Brown B (2023) 392 Safety of amlitelimab in a Phase 2a clinical trial of patients with moderate-to-severe atopic dermatitis.
Weidinger S, Cork M, Reich A, Bieber T, Lucchesi D, Rynkiewicz N, Sainson RCA, Chen R, Prandi F, van Krinks C , Stebegg M et al (2023) 353 Amlitelimab reduces serum IL-13 in a phase 2a clinical trial in atopic dermatitis without impacting T-cell expansion in a T-cell recall assay.
Weidinger S, Cork M, Reich A, Bieber T, Gilbert S, Brennan N, Wilson R, Lucchesi D, Rynkiewicz N, Stebegg M & Porter-Brown B (2023) 345 Treatment with amlitelimab—a novel non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody—reduces IL-22 serum levels in a phase 2a randomized, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis.
Siegfried EC, Cork MJ, Arkwright PD, Wollenberg A, Eichenfield LF, Ramien M, Khokhar FA, Chen Z, Zhang A & Cyr SL (2023) 337 Dupilumab treatment is not associated with an increased overall risk of infections in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis.
Ong P, Cork MJ & Armstrong A (2022) 34326 Real-world analysis of skin infections and antimicrobial use among patients with atopic dermatitis before and after initiation of dupilumab treatment.
Weidinger S, Bieber T & Cork M (2022) 34312 Treatment with amlitelimab (KY1005, SAR445229): A novel nondepleting anti-OX40Ligand (OX40L) mAb reduces IL-13 serum levels in a phase 2a randomized placebo-controlled trial in patients with moderate to severe atopic dermatitis.
Winder N & Cork M (2022) 33569 Optimization of common hand cleansers for protection from viral spread and occupational hand dermatoses.
Paller A, Eichenfield LF & Cork MJ (2022) 34655 Integrated analysis of abrocitinib for the treatment of adolescents with moderate-to-severe atopic dermatitis from the phase 3 clinical trial program.
Weidinger S, Bieber T, Cork M, Reich A, Brennan N, Quaratino S, Wilson R & Porter-Brown B (2022) 33781 Sustained and durable response up to 24 weeks after last dose observed in a phase 2a study (NCT03754309) of amlitelimab (KY1005, SAR445229) a novel nondepleting anti-OX40Ligand (OX40L) mAb in patients with moderate to severe atopic dermatitis (AD).
Simpson E, Blauvelt A, Silverberg JI, Cork M, Katoh N, Mark T, Schneider S & Wollenberg A (2022) LB946 Clinically meaningful responses achieved with tralokinumab in adults with moderate-to-severe atopic dermatitis who did not meet IGA 0/1 at initial 16-week treatment.
Paller AS, Weidinger S, Cork MJ, Marcoux D, Katoh N, Zhang H, Rossi AB, Shumel B, Zhang A, Prescilla R & Chao J (2021) 27394 Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs, symptoms, and quality of life in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial.
Paller AS, Cork MJ, Marcoux D, Wollenberg A, Prescilla R, Chen Z, Rossi AB & Shumel B (2021) 27350 Dupilumab improves Eczema Area and Severity Index regional scores across all anatomical regions in children aged 6–11 years with severe atopic dermatitis (AD).
Cork MJ, Thaçi D, Eichenfield L, Arkwright PD, Chen Z, Delevry D, O’Malley JT & Bansal A (2021) 26880 Long-term efficacy and safety data for dupilumab in a phase 3, open-label extension trial (LIBERTY AD PED-OLE) in patients aged ≥6 to <12 years with uncontrolled, moderate-to-severe atopic dermatitis (AD).
Cork MJ, Lockshin B, Blauvelt A, Chen Z, Khokhar FA, Bansal A & Prescilla R (2021) 26875 52-week laboratory safety findings from an open-label extension (OLE) study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE).

Teaching interests

My teaching interests within The University include medical undergraduate lecturing and in-clinic training plus postgraduate researcher training and mentoring. I also lecture to related courses at other universities, such as the MSc in Dermatology at Cardiff and at major international and national conferences in the field of dermatology. In addition I undertake a large number of atopic eczema related educational presentations at local, national and international level to a wide range of audiences including; pharmacists, general practitioners, hospital nurses, community nurses, midwives, paediatricians, practice nurses and patient support charities (e.g. National Eczema Society, Skin Care Campaign and Psoriasis Association).

Education of Children with Skin Diseases:

I have developed a special interest in `translating´ the complex pathophysiology of skin disease into cartoons and language that can be understood by a child of six. I presented these to the National Eczema Society and the Skin Care Campaign. I have written papers for these charities describing the content of the lectures, for example Cork et al 2000; 2002 "Skin Wars". I use the cartoons in my clinics to teach children and their parent about skin diseases. The medical students that sit-in during my clinics, suggested I incorporated the "Skin Wars" cartoons into their lectures because they made dermatology exciting. The "Skin Wars" cartoons have been disseminated to many other dermatology departments. I have assigned all commercial profits from use of the "Skin Wars" cartoons to the National Eczema Society. The "Skin Wars" teaching approach was cited as being an innovative approach to education by the judges in the Hospital Doctor Dermatology Team of the Year Awards, which our paediatric dermatology team won in 2001. This teaching method was also highlighted in the National Eczema Society Health Care Professionals Award 2004.

Professional activities and memberships

Member of the National Institute of Clinical Excellence (NICE) clinical guideline development group for the treatment of Atopic Eczema in children.
Advisor, Lecturer and developer of educational materials for the National Eczema Society, Skin Care Campaign, Psoriasis Association and Allergy UK.
Wellcome Trust Translational Grants Reviewer & Expert Panel member.
Grant Reviewer, British Skin Foundation, Psoriasis Association and Wellcome Trust.
Fellow of the Royal College of Physicians, London and Edinburgh.
Member of British Association of Dermatologists.
Member of European Academy of Dermatology and Venereology.
Member of British Society for Investigative Dermatology.
Member of European Society for Dermatological Research.
Member of British Society for Paediatric Dermatology.
Member of Dowling Dermatology Society.
Professional Member of the National Eczema Society.
Member of The Council (board) of the Psoriasis Association.
South Yorkshire Biotech Enterprise Network (SYBEN): York Pharma – Biotech company of the year, 2006.
Yorkshire Forward Bioscience Yorkshire Annual Awards: Molecular Skin Care: Recognised for Outstanding Achievements in Bioscience. Awarded to the company who has made the greatest advances in Yorkshire in 2005.
Leader of the team awarded ‘Health Care Professional Team of the Year’ by the National Eczema Society in 2004.
Leader of the team awarded ‘Hospital Doctor Dermatology Team of the Year’ 2001.

Enquiries: For Teaching & Academic Supervisory Enquiries, Post-Graduate and Undergraduate (i.e. PATs) please email:
Les Hunter & cc to Prof. Michael J. Cork
For Research Enquiries (including Pharmacological, Cosmetic & Academic) please email: Les Hunter & cc to Prof. Michael J. Cork
For Children’s Clinical NHS Enquiries please email: Elaine Cox & cc to Prof. Michael J. Cork
For Adult Clinical NHS Enquiries please email: Lucy Lowe & cc to Prof. Michael J. Cork